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ABSTRACT
Chmura, Douglas F. M.S., Department of Pharmacology and Toxicology, Wright State
University, 2011. Response of neuroinflammatory and neurodegenerative markers following sublethal sarin exposure and subsequent treatment via an in-vivo caspase inhibitor.
Organophosphorus nerve agents are amongst the most deadly chemical compounds ever
synthesized. Sarin is an organophosphate (OP) ester that irreversibly forms a phosphoester bond
at the active site of acetylcholinesterase and thereby induces a rapid and lethal cholinergic crisis.
It remains an active threat to vulnerable civilian populations due to its ease of synthesis and
known use by rogue nations and terrorist groups. Death is the most extreme consequence of sarin
toxicity. Current treatments fail to provide protection against progressive cognitive impairments
years after mild exposure. Q-VD-OPh is an in-vivo caspase inhibitor with potent anti-apoptotic
and anti-inflammatory properties. In this pilot study, adult male C57BL/6J mice were
subcutaneously injected with 0.5 LD50 sarin followed by an intraperitoneal injection of 20 mg/kg
Q-VD-OPh. Mice were sacrificed at a two-day time point followed by MALDI imaging and
immunohistochemical analysis of brain sections. Protein mass spectra of tissue sections
subjected to organic washes yielded an increase in signal sensitivity compared to untreated
sections. A non-significant upward trend in GFAP expression was observed in sarin treated
animals in contrast to Q-VD-OPh animals. Statistically significant downward trends in nuclear
NF-κB/p50-50 expression were observed in sarin treated animals in contrast to Q-VD-OPh
animals. These trends open a window to innovative research paradigms that extend beyond the
emphasis of regenerating acetylcholinesterase and managing seizures.
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I. Introduction
The History of Sarin
Sarin (GB; O-isopropyl methylphosphonofluoridate) is among the most toxic nerve
agents developed in the 20th century. Sarin derived its name from the four German scientists
accredited with its synthesis in the 1930’s: Schrader, Ambros, Rudriger, and van der Linde
(Sidell et al., 2008). In addition to sarin, the other nerve agents ie., tabun, cyclosarin, and soman
were developed in Germany during the same period (Popov et al., 2008). Designated by NATO
as the G-agents, they were originally developed for use as OP insecticides (Costa, 2006).
However, German military personnel quickly recognized their use as chemical warfare agents
(CWAs) after scientists reported symptoms of pupil eye constriction and discomfort when
working with them (Newmark, 2004).
While large stockpiles of sarin were produced by Germany during the WWII era, it was
first used as a CWA during the Iran-Iraq war of the 1980’s (Hurst et al., 2007). Approximately
45,000 and 120,000 Iranian casualties were the subject of sarin attacks by Iraqi forces (Newmark,
2004). During the Gulf war of the early 1990’s, an Iraqi munitions dump was destroyed exposing
more than 100,000 U.S. troops to sarin (Chao et al., 2010). Gulf war veterans reported symptoms
of drowsiness, short-term memory loss, attention deficits, irritability, confusion, and depression
(Abu-Qare and Abou-Donia 2002; Chao et al., 2010; McCauley et al., 2001). Studies of Gulf war
veterans four years post exposure suggested a greater risk for brain cancer deaths than unexposed
veterans (Bullman et al., 2005). White and colleagues evaluated short-term memory
performance, attention, and mood in veterans exposed to sarin and veterans not exposed to sarin
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(White, 2001). They found that veterans exposed to sarin exhibited declines in
neuropsychological performances than those that were not exposed (White et al., 2001).
Sarin is highly toxic and effective through multiple routes of exposure (Figure 1). Even
though the use of OPs was outlawed by the 1997 Chemical Weapons Warfare Convention, their
ease of synthesis and known use by terrorist groups continues to pose a security threat (Popov et
al., 2008; Trapp, 2006). For instance, in Japan of 1994 the Aum Shinrikyo religious group
attacked 600 residents of Matsumoto city killing seven and injuring 58 (Morita et al., 1995). In
the following year on March 20, Aum members released liquid sarin on five separate lines of the
Tokyo subway killing 12 people and causing an estimated 5,000 to seek medical attention
(Okumura et al., 1998).

Figure 1: Chemical structure of sarin (C4H10FO2P). Sarin is colorless, odorless, and the most
volatile of all the nerve agents. The toxicological action of sarin is due to its covalent bond
formation with the active serine site of acetylcholinesterase. Toxic effects can occur by ingestion,
inhalation, and cutaneous exposure with the liquid and or vapors.
Mechanisms and Effects of OP Toxicity
Sarin is an OP ester that irreversibly forms a phosphoester bond at the active site of
acetylcholinesterase (AChE) thereby preventing the degradation of the neurotransmitter
acetylcholine (ACh). The active site of AChE is a catalytic pocket composed of the amino acids
histidine, glutamate, and serine. When sarin initially binds to the catalytic pocket, histidine and
2

glutamate residues position the OP in place while the serine residue forms a partial covalent bond
with the fluorophosphate group (Figure 2) (Majumdar et al., 2006).

Figure 2: Initial binding of sarin to AChE. Note the alkyl group still bound.
This forms a partially unstable phosphorylated enzyme that undergoes a spontaneous timedependent dealkylation reaction known as aging (Jokanovic, 2009). It is only during this brief 40
min period that the OP can be removed from the enzyme. Eventually, the alkyl group leaves
forming a highly stable AChE phosphoester resistant to current recovery therapies (Figure 3)
(Abou-Donia, 2003; Goodman et al., 2006; Schier and Hoffman, 2004).
The permanent inhibition of AChE causes a rapid accumulation and subsequent
overstimulation of ACh at neuroeffector junctions in the central and peripheral nervous system
(CNS and PNS) (McDonough and Shih 1997). In the cholinergic system, ACh is released in
response to nerve stimulation and binds to post synaptic nerve receptors to elicit a biological
effect (Platt and Riedel, 2011). This effect is rapidly terminated through the subsequent cleavage
of ACh by the catalytic serine of AChE allowing the postsynaptic nerve to return to its original
state (Shen et al., 2002). However, when the cleavage of ACh is inhibited it causes cholinergic
3

nerves to be in a state of constant excitement resulting in acute symptoms: convulsions, seizures,
paralysis of motor function, excessive mucosal lacrimations, and death primarily from respiratory
failure (Jokanovic and Kosanovic 2010; Moretto et al., 2011).

Figure 3: Sarin aged AChE. The loss of an alkyl group results in a permanently inhibited
enzyme.
Current Treatment for OP Poisoning
The current treatment for sarin exposure is available to military and emergency response
personnel and is termed the CANA-MARK I kit (Sidell et al., 2008). The CANA-MARK I kit is
composed of three injectable drugs:
1) Atropine-relieves the symptoms of excessive ACh stimulation at muscarinic
receptors (Sidell et al., 2008).
2) 2PAM (2-pyridine aldoxime methyl chloride)-regenerates AChE by phosphoryl
group removal but only when the alkyl group is still bound (Sidell et al., 2008).
3) Diazepam-an anticonvulsant that limits brain damage from seizures (Sidell, et al.,
2008).
4

It is crucial to administer CANA-MARK I treatments immediately after OP exposure as these
treatments cannot rescue permanently bound OP-AChE adducts. Even if the current
prophylactics are given within a 40-minute period, it is inevitable that victims of OP exposure
may develop prolonged and progressive neuroinflammation and neurodegeneration (Doctor and
Saxena 2005). Sarin is still an active threat to military and civilian populations. While military
personnel are readily equipped with CANA-MARK I kits, the general population must rely on
emergency response personnel to administer treatment in a densely populated area. The
likelihood that all victims receive treatment in a sarin-induced terrorist attack is unlikely since
first responders must navigate through a heavily populated area of mass panic, identify victims
needing immediate care, and administer treatments with a narrow therapeutic time window.
Therefore, those that survive sarin exposure represent a vital proportion of the population at risk
of developing long-term adverse neurodegenerative disorders (Doctor and Saxena 2005). Hence,
the ability to attenuate OP induced neuronal cell death and inflammation would establish as a
vital improvement over current CANA-MARK I treatments.
Effects of OP Toxicity in Specific Brain Regions
While sarin causes death and acute cholinergic toxicity in small vicinities, it largely
causes chronic neurotoxic symptoms to individuals within a broader exposure radius. The
delayed onset of neurotoxic symptoms from sarin exposure results from contact to large, acutely
toxic or small subclinical doses (Jamal, 1997). Clinical symptoms persist from weeks to years
resulting in delayed type neurological and neurobehavioral abnormalities: chronic headaches,
short-term memory loss, fatigue, attention deficits, depression, anxiety, confusion, and
personality changes (Grauer et al., 2008; Jaga and Dharmani 2007; Yanagisawa et al., 2006).
Several regions within the brain inclusive of the dendate gyrus and CA2-CA3 (Cornu Ammonis
Region II-III) subfields of the hippocampus, piriform cortex, amygdala, and hypothalamus show
neuropathological lesions that correlate to neurological and neurobehavioral abnormalities linked
5

to OP exposure (Figure 4) (Spradling et al., 2011). Neurons in these brain regions are associated
with mood, judgment, emotion, learning, and memory, e.g., granular, pyramidal, and
magnocellular neurosecretory cells (Dickerson and Eichenbaum 2010; Sawchenko and Swanson
1990).
There are numerous examples of OP-induced neuronal degenerations in brain regions
correlating to learning and memory deficits. For instance, a study by Kilburn (1999), in patients
exposed to the OP chlorpyrifos demonstrated neuropsychological abnormalities in verbal
memory, cognitive function, and mood. Furthermore, rats given a dermal application of 0.1
mg/kg chlorpyrifos developed deficits in sensorimotor function (Abou-Donia et al., 2003).
Additionally, neuropathological modifications following soman exposure were observed in the
hippocampus and hypothalamus regions of rat brains (Petras, 1994). Petras and colleagues also
noted axonal degeneration was not dependent on the initiation of seizures in rats following acute
soman exposure (1994). Neurodegeneration was also present in the dendate gyrus and CA1-CA3
subfields in rats 24 hours following a 100 μg/kg intramuscular injection of sarin (Abdel-Rahman
et al., 2002). Rats that survived a 95 μg/kg injection of sarin exhibited persistent lesions in the
hippocampus, hypothalamus, and piriform cortex (Kadar et al., 1995).
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Figure 4: Brain Regions of Interest: Dendate gyrus and CA2-CA3 subfields of the
hippocampus, piriform cortex, amygdala, and hypothalamus.
The delayed symptoms of acute or subclinical doses of sarin indicate that OPs’ exert their
toxicity through neuroinflammatory and neurodegenerative processes. For instance, the presence
of inflammatory cytokines, e.g., IL-6, IL-10, IL-1β, and TNF-α have been noted in sub-lethal
exposures to organophosphates (Spradling and Dillman III 2011). Brain damage in animal
models exposed to nerve agents resulted in the increased expression of proinflammatory
cytokines, deceased or degenerating neurons, and activated microglia and astrocytes (Collombet,
2011). The recruitment of these inflammatory factors indicates that the toxicity of sarin-induced
neuropathies is potentiated by neuroinflammation. Excessive accumulation of reactive oxygen
species (ROS) leads to mitochondrial ATP depletion, proteolytic caspase (cysteine-aspartic
7

protease) induction, and DNA fragmentation that ultimately end in apoptosis. This notion is
supported by evidence that sub-lethal doses of OPs generate ROS and are thereby accountable for
neurodegenerative processes (Segura-Aguilar and Kostrzewa 2004). In addition, Abdel-Rahman
and colleagues demonstrated the apoptotic degeneration of adult male rat brain hippocampal
neurons at a 24-hour time point following a sub-lethal dose of sarin (2002). Additionally, while
rats treated with a sub-toxic dose of sarin did not show evidence of neurohistopathological lesions
at a 30-day time point, they eventually exhibited apoptotic neuropathies one year after dosing
(Abdel-Rahman et al., 2002). Recent evidence indicates that OP’s are responsible for the
amplification of apoptotic events that cause the progressive loss of neurons (Tebourbi et al.,
2011). The activation of a caspase-induced cell death pathway indicates that the toxicity of sarininduced neuropathies is also potentiated by neurodegeneration. It is worthwhile to investigate the
effects and mechanisms of sarin-induced neuroinflammation and neurodegeneration in order to
pursue the development of optimal neuroprotective agents that would provide new avenues for
targeted therapeutic drug design against nerve agent attacks in civilization and tactical warfare.
Secondary Targets of Chronic OP Exposure
It is well known that lethal doses of OP’s inhibit AChE by formation of a phosphoester at
a serine residue. Elucidation of this mechanism centered on the observation that symptoms of
cholinergic inhibition are most noticeable and life threatening. This is because the catalytic
activity of AChE transpires at a plethora of synaptic junctions throughout the peripheral and
central nervous system that vitally depend on the breakdown of ACh in order to operate normally.
However, it became perplexing when sub-lethal doses of OPs caused no obvious cholinergic
symptoms yet were linked to illnesses of delayed neuropathies such as memory loss, depression,
cognitive impairment, and debilitating motor skills (Ergun et al., 2008; Masoud et al., 2011). The
absence of cholinergic inhibition yet the delayed expression of neurodegenerative processes led to
the understanding that OP’s bind to several serine hydrolases and not just AChE alone.
8

The brain is particularly susceptible to OP poisoning because it requires high amounts of
oxygen, large quantities of ATP, possesses significant amounts of peroxidizable lipids, and
contains a low quantity of antioxidant enzymes e.g., glutathione (El-Demerdash, 2011). Sarin is a
lipophilic OP that readily crosses the blood brain barrier (BBB) and irreversibly binds to serine
hydrolases leading to the accumulation of endogenous substrates that initiate a cell death cascade
(Carter et al., 2011). Serine hydrolases belong to a large superfamily and mainly include serine
proteases, intracellular and extracellular lipases, thioesterases, phospholipases, and
cholinesterases (including AChE) (Simon and Cravatt 2010). All of these enzymes hydrolyze
their substrates at a nucleophilic serine residue within a catalytic triad site. For instance,
lysolecithin is a major phospholipid in glial cells that is metabolized by NTE-LysoPLA
(Neuropathy Target Esterase-Lysophospholipase) (Quistad et al., 2003). Inhibition of NTELysoPLA with OPs led to elevated levels of lysolecithin and subsequent demyelination of
neurons (Casida and Quistad 2004). Since hundreds of serine hydrolases are expressed in the
human proteome, OP inhibition with secondary targets may alter downstream effectors and
markers that govern neuroinflammatory and neurodegenerative processes (Figure 5) (Thompson
et al., 2010).
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Figure 5: Secondary targets of OP exposure. AChE is one of many hundreds of serine
hydrolases and other secondary targets altered after OP exposure.
Mechanism of Apoptosis
Apoptosis is an operational process of cell death distinguished by lack of an
inflammatory response, caspase activation, substrate cleavage, DNA fragmentation 180bp’s in
length, plasma membrane blebbing, and formation of apoptotic bodies that are phagocytized by
resident microglia (Van Cruchten and Van Den Broeck 2002; Trump et al., 1997). There are two
types of caspases that mediate apoptosis i.e., initiator caspases 8, 9, and 10 and effector caspases
3, 6, and 7 (Inoue et al., 2009). Initiator caspases cleave inactive pro-forms of effector caspases
that in turn cleave protein substrates within the cell triggering the apoptotic process. There are
two main apoptotic pathways in humans that arise from extrinsic or intrinsic cellular signals
(Figure 6) (Brown, 2004). The extrinsic pathway is characterized by caspase 8/10 activation after
cell surface death receptor ligation with TNF-α (Fulda and Debatin 2006). The intrinsic pathway
is distinguished by caspase 9/3 activation after mitochondrial release of cytochrome C into the
10

cytosol (Fulda and Debatin 2006). Both pathways converge at caspase 3, even though the
characterization of the extrinsic pathway is not distinguished by the cleavage of this effector
caspase.

Figure 6: Extrinsic and intrinsic pathways of apoptosis.
Proinflammatory and Anti-inflammatory NF-κB Activation Pathways
NF-κB (nuclear factor kappa-b) is expressed in neurons and glial cells in the CNS and
plays vital roles in inflammatory and immunological reactions (Mefferet and Baltimore 2005;
O’Neill and Kaltscmidt 1997). Inactive NF-κB dimers are localized in the cytoplasm by IκB
precursors in nonstimulated cells (Nishikori, 2005). Active NF-κB dimers are comprised of a
variety of Rel family proteins and are liberated from IκB precursors through IκB phosphorylation
in stimulated cells (Ghosh et al., 1998; Singh and Jiang, 2004). There are two active NF-κB
dimers responsible for the nuclear transcription of proinflammatory and anti-inflammatory genes:
The NF-κB/p50-65 heterodimer and the NFκB/p50-p50 homodimer, respectively (Figure 7)
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(Singh and Jiang, 2004). Thus, the NF-κB p50/p65 heterodimer is anti-inflammatory and proapoptotic whereas the NF-κB/p50-p50 homodimer is proinflammatory and anti-apoptotic.

Figure 7: Proinflammatory and anti-inflammatory pathways of activated NF-KB dimers.
Nuclear translocation of the NF-KB/p50-50 homodimer induces transcription of antiinflammatory cytokines whereas nuclear translocation of the NF-KB/p50-65 heterodimer induces
transcription of proinflammatory cytokines.
Since apoptosis is characterized by lack of an inflammatory response, it is reasoned that
an environment promoting NF-KB/p50-p50 activation may be triggered after initial exposure to
sub-lethal amounts of OPs. However, neuroinflammation has been reported in animal models
exposed to OP’s. Therefore, it is also reasoned that an environment promoting NF-KB/p50-p65
activation may also be triggered after initial exposure to sub-lethal doses of OPs. Since it is
12

unknown if either neurodegeneration or neuroinflammation predominantly occur following sublethal OP exposure, it is unknown if the nuclear expression of NF-κB/p50-p50 stained cells will
show an upward, downward, or no trend at all in sarin treated animals.
An endpoint of OP induced neuropathies results in the axonal degeneration of neurons
resulting in the formation of a glial scar around the damaged tissue. Astrocytes are a subtype of
glial cell in the CNS that is star-shaped with many filaments that envelope neurons and their
synapses (Sofroniew and Vinters 2010). Astrocytes express the intermediate filament GFAP
(glial fibrillary acidic protein) and upon activation increase its expression resulting in the
proliferation of these cells around wounded areas in order to prevent additional damage to
adjacent tissues (Sofroniew and Vinters 2010). Hence, GFAP expression is a marker for neuronal
injury. In this study, we expect to see a greater number of GFAP stained cells in sarin treated
animals.
Exploration of Endogenous Biomarkers
OP esters covalently bind and inhibit enzymes of the serine hydrolase family, including
AChE (Thompson, 2010). Other than OP-AChE inhibition, the connection between OP-ChE
inhibition and the resulting downstream cellular/toxic outcomes have not been established
(Rubino et al., 2009). Matrix-assisted laser desorption/ionization (MALDI) imaging has emerged
as a powerful tool to quantify biomarkers in-situ by offering high-throughput, fingerprinting, and
identification of peptides after formulation with a matrix (Stoeckli et al., 2001). The matrix
consists of organic solvents mixed with water in order to dissolve hydrophobic and hydrophilic
molecules in tissue. Typically, a matrix co-crystallizes with analytes in tissue after the solvents
evaporate during the application procedure. The matrix absorbs the destructive energy of the
laser and transfers its charge to peptides resulting in the formation of quasimolecular ions (Read,
2011). These ions may consist of the peptide mass [M] and an added proton [M+H]+, an added
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sodium [M+Na]+, or a removed proton [M+H]- (Levsen et al., 2007; Stoll and Rollgen 1981).
Before the development of MALDI imaging, quasimolecular ions were displayed as a mass
spectrum, a histogram of peptide abundance versus its mass to charge (m/z) ratio. With MALDI
imaging, a mass spectrum is displayed in addition to a representative image of its spatial
distribution within whole body tissue sections (Reyzer and Caprioli 2007).
MALDI mass spectrometers are operational in either linear mode or reflector mode and
use time of flight (TOF) hardware to determine a peptides m/z ratio (Domon and Aebersold
2006). In linear mode, ions are pulsed by a laser into an ion source and accelerated by an electric
field into a linear flight tube onto a detector (Figure 8) (Rappsilbera et al., 2003). This allows
ions with a smaller mass to charge ratio to reach the detector faster than ions with a greater mass
to charge ratio.

Figure 8: MALDI-TOF linear mode.
However, in many instances the spectra produced in linear mode produces broad peaks with poor
mass resolution (Ashcroft, 1997). This is commonly caused when ions of the same mass have
14

slight differences in ionization energy (Weston, 2010). Hence, ions of the same mass reach the
detector at different speeds when they should reach the detector at the same speeds. In reflector
mode, ions are accelerated by an electric field into a linear flight tube to an optic mirror that
subjects ions to a uniform repulsive field (Figure 9) (Muddiman et al., 1997). The repulsive field
redirects their time of flight through a reflector flight tube onto a detector (Flensburg et al., 2004).
Thus, ions with greater ionization energy will penetrate deeper into the repulsive field and hence
will take longer to reach the detector. This compensates for the initial energy spread of ions of
the same mass and improves the resolution of a mass spectrum (Kurnosenko and Moskovets
2010).

Figure 9: MALDI-TOF reflector mode.
This study will employ the principles of MALDI imaging to explore unknown
biomarkers in whole brain tissue sections of mice in control and treated groups. A broad range of
low molecular weight peptides will be ionized in reflector mode with a α-cyano-4hydroxycinnamic acid (CHCA) matrix solution dissolved in a common solvent. CHCA is a
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suitable matrix for the detection of peptides with a molecular mass ranged between 500-3000 Da
with a 0.5 Da precision (Fournier et al., 2003).
Potential Therapy: In-vivo Caspase Inhibitor Q-VD-OPh
During the last decade, the understanding of apoptosis has focused scientists on
formulating inhibitors that prevent caspase activation (Barut et al., 2005; Li et al., 2000). Broadspectrum caspase inhibitors permeate the cell membrane and alkylate the active cite cysteine of
caspases and irreversibly block apoptosis by preventing caspase activation, substrate cleavage,
and DNA ladder formation (Caserta et al., 2003). However, many of these caspase inhibitors are
conjugated to toxic fluoromethylketone (FMK) groups that limits there use in animal studies
(Chauvier et al., 2006; Van Noorden, 2001). For instance, FMK inhibitors require doses greater
than 50 μM to be effective but are also toxic at these doses as well (Brown, 2004). In contrast to
FMK type inhibitors, Q-VD-OPh (Quinolyl-valyl-O-methylaspartyl-[2,6 difluorophenoxy]methyl ketone) was demonstrated to be non-toxic and highly effective at doses as low as 5 μM in
tissue cultures (Caserta et al., 2003).
Due to its safety and potency in-vitro, applications of Q-VD-OPh in-vivo have also
demonstrated it to be nontoxic and effective as well. In animal models of stroke and CNS
damage, Q-VD-OPh prevented neurodegeneration and restrained neuroinflammatory responses
(A. Çolak et al., 2009; Abrahamson et al., 2006; Braun et al., 2007; Renolleau et al., 2007).
Furthermore, Q-VD-OPh has demonstrated to cross the BBB and inhibit all major apoptotic
pathways in humans, caspase 8/10, and caspase 9/3 (Caserta et al., 2003). Mice injected with an
intraperitoneal dose of 120 mg/kg Q-VD-OPh did not show evidence of toxicity (Melnikov et al.,
2002). Presently, the recommended dose for in-vivo applications is 20 mg/kg (Caserta et al.,
2003).
Q-VD-OPh consists of the amino acids valine and aspartic acid, coupled to a C-terminal
O-phenoxy group (Figure 10) (Southerland et al., 2010). It is thought the O-phenoxy moiety may
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provide a non-toxic leaving group and the quinolyl group may act as a peptidomimetic thereby
elevating the active intracellular concentration of inhibitor present (Southerland et al., 2010).
Due to its nontoxcity, potency, and membrane permeability, the current study will examine the
effectiveness of Q-VD-OPh against neuroinflammation and neurodegeneration in the brains of
mice exposed to a single subcutaneous injection of the nerve agent sarin.

Figure 10: Chemical structure of Q-VD-OPh.
Use of CBDP: A Carboxylesterase Scavenger
Caboxylesterase is an endogenous chemical scavenger that inactivates OPs. Rodents
have a high level of carboxylesterase compared to humans that inactivates OPs before they can
interact with AChE to produce the classical symptoms of OP poisoning (Clement and Ernhardt
1990). Cresylbenzodioxaphosphorin oxide (CBDP) is a carboxylase scavenger that inhibits
excess rodent carboxylesterase and efficiently increases rodents’ susceptibility to OP poisoning,
making their exposure at low doses more representative of human exposure (Masson, 2011).
Preliminary work has demonstrated that a dose of 1.5mg/kg CBDP specifically blocks
carboxylesterase, and potentiates the response of C57BL/6J mice to sarin without causing toxicity
(Jimmerson et al., 1989).
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Hypothesis and Specific Aims
The large body of evidence indicating that the current treatment regimes of OP poisoning
fail to prevent neuroinflammation and neurodegeneration and the relatively novel concept that QVD-OPh is potentially useful as an in-vivo neuroprotectant beyond a 40 minute administration
window lead to the development of the following hypothesis: Sarin-induced, prolonged or
progressive CNS neuro-inflammatory responses, and neurodegeneration can be attenuated by use
of an in-vivo caspase inhibitor, Q-VD-OPh. In order to study the possible neuroinflammatory and
neurodegenerative pathologies following sub-lethal OP exposure, and whether these pathologies
could be attenuated by therapeutic use of Q-VD-OPh, we divided these pathologies into three
specific aims.
Specific Aim 1
Establish neuroinflammatory and neurodegenerative markers of sarin exposure.
Specific Aim 2
Test the hypothesis that Q-VD-OPh can attenuate progressive sarin-induced neurodegeneration.
Specific Aim 3
Test the hypothesis that Q-VD-OPh can attenuate prolonged sarin-induced neuroinflammation.
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II. Materials and Methods
Animals
An AAALAC (Association for the Assessment and Accreditation of Laboratory Animal
Care) standard facility held adult male C57BL/6J mice on a 12-hour light/dark cycle with open
access to a standard pellet diet and water. Mice were acclimated to their environment for seven
days and subjected to three days of handling before dosing. Mice were subjected to a dosing
sequence that mimics chronic OP toxicity in humans via the injection of 1.5 mg/kg CBDP 30 min
before a 0.5 LD50 injection of sarin. To ensure that our caspase inhibitor provided
neuroprotection beyond the limitations of CANA-MARK-1 treatments, mice received a 20 mg/kg
injection of Q-VD-OPh 40 minutes after sarin injections. Mice were divided into the following
groups and classified according to the treatments administered:
1) Saline: Animals that received a glycol-saline-saline injection series.
2) CBDP: Animals that received a CBDP-saline-saline injection series.
3) Sarin: Animals that received a CBDP-sarin-saline injection series.
4) Q-VD-OPh: Animals that received a CBDP-sarin-Q-VD-OPH injection series.
Drugs
CBDP was diluted in propylene glycol and 5% ethanol to a dose of 1.5 mg/kg. Sarin
(USAMRICD, Aberdeen Proving Ground, MD) was obtained as a 1.9 mg/ml stock solution and
subsequently diluted in 0.9% saline to a dose of 46 µg/kg (0.5 LD50). Q-VD-OPh was diluted in
0.9% saline to a dose of 20 mg/kg. The first two treatments of an injection series were dispensed
subcutaneously whereas the third treatments of an injection series were dispensed
intraperitoneally. Mice were sacrificed two days post treatment administration.
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Tissue Collection and Sectioning
Mice were sacrificed followed by the collection of brain tissue. Tissue was flash frozen
in isopentane for 30 seconds and stored at -80°C until sectioned. The brains were mounted on a
cryocassette but not completely covered with tissue freezing medium (Triangle Biomedical
Sciences, Durham, N.C.) in order to keep limited tissue sections freely exposed to the cryotome.
This ensured that polymers within the tissue-freezing medium did not suppress analyte signals
during analysis with the mass spectrometer. Brains were coronally sliced on three different
cryotomes: Leica CM3050, Thermo Shandon Cryotome E, and a Reichert-Jung Cryocut 1800.
Tissue was sliced at a thickness of 12μm at -20°C throughout brain regions inclusive of the
dendate gyrus, CA2-CA3, piriform cortex, amygdala, and hypothalamus between 0-5 mm rostral
from the intraural line. Brain regions were selected using landmarks in The Mouse Brain in
Stereotaxic Coordinates (Paxinos and Franklin, 2008), and confirmed after the consultation of
two experts. Sections for immunofluorescent staining were thaw mounted on UltraStick slides
(Gold Seal Products, Portsmouth, NH), placed in a desiccator for 45 min at 21°C, and then stored
at -20°C. Sections for MALDI Imaging were thaw mounted on conductive glass slides (Bruker
Corporation, Bremen, Germany) and placed in a desiccator for 45 min at 21°C. Sections were
then washed in a 70% isopropanol solution followed by a 95% isopropanol solution for 30
seconds each. Afterwards, sections were dried in a desiccator for 45 min at 21°C and then stored
at -20°C.
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GFAP Immunofluorescent Staining
Tissue sections were dried in a desiccator for 45 min at 21°C. A liquid repellent PAP pen
(Daido Sangyo Company, Tokyo, Japan) was used to draw boundaries around sections and let dry
for 10-15 min. Tissue sections were fixed with 2% paraformaldehyde in 1XPBS + 0.2% Triton
X-100 (TX-100) for 30 min at 4°C in a moist chamber. A moist chamber is a plastic tupperware
container with a tight lid where slides are laid upon pairs of glass rods placed on absorbent paper
soaked with distilled water. All incubations at 4°C were performed in a moist chamber. Sections
were washed 5 times in 1XPBS for 5 min each at 21°C. Sections were then blocked with 10%
normal goat serum (NGS) in 1XPBS for 1 hr at 4°C. Next, sections were incubated with primary
rabbit anti-GFAP (Invitrogen, Camarillo, CA) at a 1:400 dilution in 10% NGS + 1XPBS for 1 hr
at 4°C. For a negative control, serial sections were incubated with normal rabbit serum (NRS)
diluted 1:400 in 10% NGS + 1XPBS for 1 hr at 4°C. Afterwards, sections were washed 5 times
in 1XPBS for 5 min each at 21°C. Sections were then incubated with secondary biotin-SPconjugated donkey anti-rabbit (Jackson Immunoresearch Laboratories, West Grove, PA) at a
1:200 dilution in 10% NGS + 1XPBS for 1 hr at 4°C. Next, sections were washed 5 times in
1XPBS for 5 min each at 21°C. Afterwards, sections were incubated with Cy3-conjugated
streptavidin (Jackson Immunoresearch Laboratories, West Grove, PA) at a 1:200 dilution in
1XPBS for 1 hr at 4°C. Sections were then washed 3 times in 1XPBS for 5 min each at 21°C.
Next, sections were incubated with Hoechst stain 33342 (Intergen) at a 1:200 dilution in 1XPBS
for 5 min at 21°C. Hoechst stain labels all nuclei and allows for the visualization of brain
structures. Afterwards, sections were washed once in 1XPBS for 5 min at 21°C. Then, slides
were mounted with gel mount mounting medium (Biomedia, Foster City, CA) using Gold Seal®
coverglass slips (Electron Microscopy Sciences, Hatfield, PA) and stored overnight at 4°C before
image capture.
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NF-κB Immunofluorescent Staining
Tissue sections were stained for NF-κB as described above for GFAP staining with the
exception of using primary rabbit anti-NF-κB p50 (Santa Cruz Biotechnology, Santa Cruz, CA)
diluted 1:300.
Image Capture
Fluorescently stained sections of the dendate gyrus, CA2-CA3 sub-field, piriform cortex,
amygdala, and hypothalamus brain regions were viewed on a Leica DMR microscope equipped
with a Leica DFC 310 FX camera. Exposure times were set for each brain region at an optimal
magnification for each stain to ensure the image was not over or under saturated with fluorescent
light. Images were respectively captured under the LP 590 (red) and the BP 470/40 (UV)
suppression filters to ensure UV light did not bleach Cy-3 labeled cells. Individual images were
layered with Leica Application Suite software v.3.7.0 (Leica Microsystems, Heerbrugg,
Switzerland) to create a single image overlay of Cy-3 GFAP and NF-κB stained cells and
Hoechst 33342 stained nuclei. NF-κB and GFAP stained sections were captured at 40X and 20X
magnifications respectively.
MALDI Imaging
Tissue sections were thawed in a desiccator for 45 min at 21°C. Then, three white out
marks were spotted around the sections. The white out marks serve as teach points that are
visible on the optical image and underneath the matrix layer in the camera optic. An optical
image of the sections was captured with an Epson Perfection V200 photo office scanner. The
matrix solution (10 mg/ml) was prepared by dissolving CHCA (Acros Organics, Morris Plains,
NJ) in 50% acetonitrile (ACN), 0.2% trifluoroacetic acid (TFA), and brought to volume with
water. Then, sections were placed in a fume hood and the matrix solution was applied with a
chromatography sprayer (Sigma-Aldrich, St. Louis, MO) in a series of 15 spray cycles at 26 psi.
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Each spray cycle was a single application of matrix that lasted between 1-2 seconds in order to
build an even matrix layer of extracted peptides. Spray cycles were discontinued when 90% of
the tissue was covered in matrix crystals. Afterwards, the sections were placed in a desiccator for
45 min at 21°C. Dried sections were mounted on a MTP slide adapter (Bruker Corporation,
Bremen, Germany) and loaded into a Bruker Autoflex III equipped with a SmartBeam laser and
an electrostatic reflector. Protein mass spectra ranging from 1000 to 5000 m/z were acquired
from each spot in an automated fashion in linear positive-ion mode using a delay time of zero
nanoseconds. Peptides were ionized with a pulsed nitrogen laser set at 79% intensity and
accelerated with a 7.95kV electrical field onto a detector suppressing up to 50 Da. Ions were
identified at a sample rate of 2.00 GS/s with a 20X detector gain set at 100mV. All spectra were
the sum of 200 individual laser shots collected in 100-shot increments within each matrix spot.
The laser position was moved within the spot between each incremental step. Spectra were
processed using fleximaging v.2.1 (Bruker Corporation, Bremen, Germany) that include24d
baseline correction and alignment. Evaluation of results included the presence or absence of
signals and intensity of background.
Data/Statistical Analysis
Image overlays were opened in ImageJ v.1.45 and positively labeled cells within defined
areas were counted using the cell counter plug-in. Areas for GFAP stained dendate gyrus, CA2CA3 sub-field, piriform cortex, amygdala, and hypothalamus regions were 641 x 479 μm (Figure
11). Areas for NF-κB p50 stained CA2-CA3 sub-field, piriform cortex, amygdala, and
hypothalamus regions were 321 x 240 μm (Figure 12). Counts from one section from each
animal were averaged to obtain a mean cell count for each region. Cell counts were uploaded
into Graphpad Prism v.5.01 where one way ANOVA was used to evaluate the overall
significance. A Tukey’s multiple comparison post-hoc test (with correction for groups of
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different sizes) was used to test for individual group differences. All values are reported as mean
± standard deviation. P-values < 0.05 were accepted as statistically significant.

Figure 11: Representative image of a GFAP labeled tissue section (12 μm) assessed for cell
counting. Only filament bearing cells showing their nucleus in the plane of section (641 x 479
μm) were recorded. Arrows: Examples of GFAP labeled astrocytes. Scale bar represents 100
μm.
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Figure 12: Representative image overlay of a NF-κB/p50-p50 and nuclei labeled tissue section
(12 μm) assessed for cell counting. A primary NFκB/p50 antibody was used to label the inactive
NFκB/p105 precursor complex that holds the NFκB/p50-50 dimer in the cytoplasm and liberated
NF-κB/p50-p50 in the nucleus. Cytoplasmic NFκB/p50-50 was characterized when it did not
overlap nuclei (single-headed arrow). Nuclear NF-κB/p50-p50 was characterized when it did
overlap nuclei (double-headed arrow). Characterized cells were recorded in a 321 x 240 μm
section plane. Scale bar represents 50 μm.
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III. Results
Chemical Treatment of Tissue Sections for MALDI Imaging
MALDI Imaging is a technique that allows for the study of the spatial arrangement of
molecules within biological tissues. A typical preparation procedure involves the application of a
matrix spray onto thaw mounted tissue sections that are then dried and introduced to the vacuum
inlet of the mass spectrometer; where a laser generates quasimolecular ions displayed as images
(Figure 13).

Figure 13: General methodology developed for the spatial analysis of tissue by MALDI Imaging
mass spectrometry.
The detection of neuropeptides in the brain is challenging since it is primarily composed of lipids
that suppress the spectral quality of neuropeptides (Fournier et al., 2003; Lemaire et al., 2006).
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To improve signal sensitivity, a tissue washing method using organic solvents traditionally used
for lipid extraction was adopted from Seeley and colleagues (Seeley et al., 2008) and applied to
this aim of the study. Four separate solvents were prepared and separate tissue samples from a
spare mouse were submerged in the following solvents for 30s each:
1) 70% isopropanol followed by 95% isopropanol (Figure 14)
2) 70% ethanol followed by 90% ethanol + 9% acetic acid (Figure 15)
3) 70% methanol followed by 95% methanol (Figure 16)
4) 2 X 100% xylene (Figure 17)
The 1374 m/z peak is highlighted in figures 14-17 to clarify the intensity differences of the
organic solvent treatments. While the 1350 m/z peak was also included in the chemical treatment
analysis, it was not highlighted in figures 14-17 since the intensity differences of a single selected
peak are displayed with an enhanced clarity rather than multiple selected peaks (Flex Imaging 2.1
User Manual, 2008). After MALDI-TOF imaging analysis, our data suggested that the 70%
isopropanol + 95% isopropanol wash yielded the greatest signal intensity of all the washes
(Figure 19).
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Figure 14: MALDI-TOF mass spectra of a 70% isopropanol followed by a 95% isopropanol
treated mouse brain section (12 μm) recorded in linear positive-ion mode. The 1374 m/z peak is
highlighted with a vertical red line in the spectrum display. Right upper panel represents the
whole tissue MALDI image. The intensity of the 1374 m/z peak is denoted by the intensity
legend. Scale bar represents 5mm.
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Figure 15: MALDI-TOF mass spectra of a 70% ethanol followed by a 90% ethanol + 9% acetic
acid treated mouse brain section (12 μm) recorded in linear positive-ion mode. The 1374 m/z
peak is highlighted with a vertical red line in the spectrum display. Right upper panel represents
the whole tissue MALDI image.

Figure 16: MALDI-TOF mass spectra of a 70% methanol followed by 95% methanol treated
mouse brain section (12 μm) recorded in linear positive-ion mode. The 1374 m/z peak is
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highlighted with a vertical red line in the spectrum display. Right upper panel represents the
whole tissue MALDI image.

Figure 17: MALDI-TOF mass spectra of a 2 X 100% xylene treated mouse brain section (12
μm) recorded in linear positive-ion mode. The 1374 m/z peak is highlighted with a vertical red
line in the spectrum display. Right upper panel represents the whole tissue MALDI image.
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Figure 18: MALDI-TOF mass spectra of an untreated mouse brain section (12 μm) recorded in
linear positive-ion mode. The area where the 1374 m/z peak would be is highlighted with a
vertical red line in the spectrum display. Right upper panel represents the whole tissue MALDI
image.
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Figure 19: Average number of peak variations recorded from the MALDI-TOF MS in linear
positive-ion mode acquired from mouse brain sections washed or not washed for 30s with
different solvent systems in the m/z range from 1350 to 1374. Isopropanol: 70% isopropanol
followed by 95% isopropanol; Acetic Acid: 70% ethanol followed by 90% ethanol + 9% acetic
acid; Methanol: 70% methanol followed by 95% methanol; Xylene: 2 X 100% xylene;
Untreated: Sections were not treated with an organic solvent. Sections desiccated for 45 min at
21°C before application of the matrix.
MALDI Imaging for Endogenous Biomarkers
After determining that the isopropanol wash yielded the greatest signal sensitivity,
proteomic profiles in the m/z range of 1000 to 5000 were generated for control and treated
animals with a Bruker Autoflex III MALDI-TOF/TOF mass spectrometer (Figures 20-24). The
functional vacuum pressure (8X10-7 mbar) of the reflectron flight tube could not be obtained due
to inherent technical difficulties of the reflectron turbomolecular pump hardware. Thus, protein
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mass spectra were recorded in linear positive-ion mode for method development purposes only.
The 1835 m/z peak is shown as a representative peak in figures 20-24 since it displayed the most
noticeable change in intensity across control and treated animals. However, the differences of
intensity and localization of the 1835 m/z peaks across treatment groups were not quantified due
to the presence of broad peaks with resolving power inaccuracies.

Figure 20: MALDI-TOF mass spectra of a saline treated mouse brain section (12 μm) recorded
in linear positive-ion mode. The 1835 m/z peak is highlighted with a vertical red line in the
spectrum display. Right upper panel represents the raw whole tissue image adjacent to its
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MALDI image. The intensity of the 1835 m/z peak is denoted by the intensity legend. Scale bar
represents 5mm.

Figure 21: MALDI-TOF mass spectra of a 1.5 mg/kg CBDP treated mouse brain section (12
μm) recorded in linear positive-ion mode. The 1835 m/z peak is highlighted with a vertical red
line in the spectrum display. Right upper panel represents the raw whole tissue image adjacent to
its MALDI image.
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Figure 22: MALDI-TOF mass spectra of a 1.5mg/kg CBDP + 46µg/kg sarin treated mouse brain
section (12 μm) recorded in linear positive-ion mode. The 1835 m/z peak is highlighted with a
vertical red line in the spectrum display. Right upper panel represents the raw whole tissue image
adjacent to its MALDI image.

Figure 23: MALDI-TOF mass spectra of a 1.5mg/kg CBDP + 4µg/kg sarin + 20mg/kg Q-VDOPh treated mouse brain section (12 μm) recorded in linear positive-ion mode. The 1835 m/z
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peak is highlighted with a vertical red line in the spectrum display. Right upper panel represents
the raw whole tissue image adjacent to its MALDI image.

Figure 24: MALDI-TOF mass spectra of a blank section on a conductive glass slide recorded in
linear positive-ion mode. The area where the 1835 m/z peak would be is highlighted with a
vertical red line in the spectrum display. Right upper panel represents the raw blank image
adjacent to its MALDI image.
GFAP Immunofluorescent Staining
GFAP is an intermediate filament protein of astroglia and is a marker for neuronal injury.
An increase in GFAP expression is an indication of trauma to these cells. GFAP staining in the
dendate gyrus from negative control mice (Figure 25, A1-A3) showed no positive staining
compared to CBDP (Figure 25, B1-B3), sarin (Figure 25, C1-C3), and Q-VD-OPh (Figure 25,
D1-D3) treated mice. Analysis of cell counts in the dendate gyrus of mice revealed an upward
trend in GFAP expression following sarin injection compared to CBDP and Q-VD-OPh treated
animals (Figure 26). Additionally, Q-VD-OPh treated mice showed a downward trend in GFAP
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expression than sarin treated animals but an upward trend in GFAP expression than CBDP treated
animals.
GFAP staining in the CA2-CA3 sub-region from negative control mice (Figure 27, A1A3) showed no positive staining compared to CBDP (Figure 27, B1-B3), sarin (Figure 27, C1C3), and Q-VD-OPh (Figure 27, D1-D3) treated mice. Analysis of cell counts in the CA2-CA3
sub-region of mice revealed an upward trend in GFAP expression following sarin injection
compared to CBDP and Q-VD-OPh treated animals (Figure 28). Additionally, Q-VD-OPh
treated mice showed a downward trend in GFAP expression than sarin treated animals but an
upward trend in GFAP expression than CBDP treated animals.
GFAP staining in the piriform cortex from negative control mice (Figure 29, A1-A3)
showed no positive staining compared to CBDP (Figure 29, B1-B3), sarin (Figure 29, C1-C3),
and Q-VD-OPh (Figure 29, D1-D3) treated mice. Statistical analysis of cell counts in the
piriform cortex of mice revealed an upward trend in GFAP expression following sarin injection
compared to CBDP and Q-VD-OPh treated animals (Figure 30). Additionally, Q-VD-OPh
treated mice showed a downward trend in GFAP expression than sarin treated animals but an
upward trend in GFAP expression than CBDP treated animals.
GFAP staining in the amygdala from negative control mice (Figure 31, A1-A3) showed
no positive staining compared to CBDP (Figure 31, B1-B3), sarin (Figure 31, C1-C3), and QVD-OPh (Figure 31, D1-D3) treated mice. Statistical analysis of cell counts in the amygdala of
mice revealed an upward trend in GFAP expression following sarin injection compared to CBDP
and Q-VD-OPh treated animals (Figure 32). Additionally, Q-VD-OPh treated mice showed a
downward trend in GFAP expression than sarin treated animals but a nominal upward trend in
GFAP expression than CBDP treated animals.
GFAP staining in the hypothalamus from negative control mice (Figure 33, A1-A3)
showed no positive staining compared to CBDP (Figure 33, B1-B3), sarin (Figure 33, C1-C3),
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and Q-VD-OPh (Figure 33, D1-D3) treated mice. Statistical analysis of cell counts in the
hypothalamus of mice revealed an upward trend in GFAP expression following sarin injection
compared to CBDP and Q-VD-OPh treated animals (Figure 34). Additionally, Q-VD-OPh
treated mice showed a downward trend in GFAP expression than sarin treated animals but an
upward trend in GFAP expression than CBDP treated animals.
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Figure 25: Alterations of GFAP expression in the dendate gyrus at 2 days following exposure
across treatment groups. A1-A3 is an example from a negative control for the staining protocol;
A3, is an overlay of A1 and A2. B1-B3 is an example from a mouse treated with 1.5mg/kg
CBDP; B3, is an overlay of B1 and B2. C1-C3 is an example from a mouse treated with
1.5mg/kg CBDP + 46µg/kg sarin; C3, is an overlay of C1 and C2. D1-D3 is an example from a
mouse treated with 1.5mg/kg CBDP + 46µg/kg sarin + 20mg/kg Q-VD-OPh; D3 is an overlay of
D1 and D2. Images were captured at 20X magnification. Scale bar represents 100µm.
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Figure 26: Dot plot showing the mean number of GFAP positive cells in µm2 per unit area (641
x 479 µm2) in the dendate gyrus of mice across different treatment groups. CBDP mice received
1.5mg/kg CBDP + saline + saline, sarin mice received 1.5 mg/kg CBDP + 46µg/kg sarin + saline,
and Q-VD-OPh mice received 1.5mg/kg CBDP + 46µg/kg sarin + 20mg/kg Q-VD-OPh.
Animals were treated with a single dose of each treatment and analyzed 2 days post exposure.
Each bar represents the mean ± S.D. per group (CBDP, n=2; sarin, n=3; Q-VD-OPh, n=2). F2,4=
2.026; A p-value < 0.05 was considered significant.
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Figure 27: Alterations of GFAP expression in the CA2-CA3 region at 2 days following exposure
across treatment groups. A1-A3 is an example from a negative control for the staining protocol;
A3, is an overlay of A1 and A2. B1-B3 is an example from a mouse treated with 1.5mg/kg
CBDP; B3, is an overlay of B1 and B2. C1-C3 is an example from a mouse treated with
1.5mg/kg CBDP + 46µg/kg sarin; C3, is an overlay of C1 and C2. D1-D3 is an example from a
mouse treated with 1.5mg/kg CBDP + 46 µg/kg sarin + 20mg/kg Q-VD-OPh; D3 is an overlay of
D1 and D2. Images were captured at 20X magnification. Scale bar represents 100µm.
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Figure 28: Dot plot showing the mean number of GFAP positive cells in µm2 per unit area (641
x 479 µm2) in the CA2-CA3 region of mice across different treatment groups. CBDP mice
received 1.5mg/kg CBDP + saline + saline, sarin mice received 1.5 mg/kg CBDP + 46µg/kg sarin
+ saline, and Q-VD-OPh mice received 1.5mg/kg CBDP + 46µg/kg sarin + 20mg/kg Q-VD-OPh.
Animals were treated with a single dose of each treatment and analyzed 2 days post exposure.
Each bar represents the mean ± S.D. per group (CBDP, n=2; sarin, n=3; Q-VD-OPh, n=2). F2,4=
0.8001; A p-value < 0.05 was considered significant.
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Figure 29: Alterations of GFAP expression in the piriform cortex at 2 days following exposure
across treatment groups. A1-A3 is an example from a negative control for the staining protocol;
A3, is an overlay of A1 and A2. B1-B3 is an example from a mouse treated with 1.5mg/kg
CBDP; B3, is an overlay of B1 and B2. C1-C3 is an example from a mouse treated with
1.5mg/kg CBDP + 46µg/kg sarin; C3, is an overlay of C1 and C2. D1-D3 is an example from a
mouse treated with 1.5mg/kg CBDP + 46 µg/kg sarin + 20mg/kg Q-VD-OPh; D3 is an overlay of
D1 and D2. Images were captured at 20X magnification. Scale bar represents 100µm.
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Figure 30: Dot plot showing the mean number of GFAP positive cells in µm2 per unit area (641
x 479 µm2) in the piriform cortex of mice across different treatment groups. CBDP mice received
1.5mg/kg CBDP + saline + saline, sarin mice received 1.5 mg/kg CBDP + 46µg/kg sarin + saline,
and Q-VD-OPh mice received 1.5mg/kg CBDP + 46µg/kg sarin + 20mg/kg Q-VD-OPh.
Animals were treated with a single dose of each treatment and analyzed 2 days post exposure.
Each bar represents the mean ± S.D. per group (CBDP, n=2; sarin, n=3; Q-VD-OPh, n=2). F2,4=
3.532; A p-value < 0.05 was considered significant.
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Figure 31: Alterations of GFAP expression in the amygdala at 2 days following exposure across
treatment groups. A1-A3 is an example from a negative control for the staining protocol; A3, is
an overlay of A1 and A2. B1-B3 is an example from a mouse treated with 1.5mg/kg CBDP; B3,
is an overlay of B1 and B2. C1-C3 is an example from a mouse treated with 1.5mg/kg CBDP +
46µg/kg sarin; C3, is an overlay of C1 and C2. D1-D3 is an example from a mouse treated with
1.5mg/kg CBDP + 46 µg/kg sarin + 20mg/kg Q-VD-OPh; D3 is an overlay of D1 and D2.
Images were captured at 20X magnification. Scale bar represents 100µm.
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Figure 32: Dot plot showing the mean number of GFAP positive cells in µm2 per unit area (641
x 479 µm2) in the amygdala of mice across different treatment groups. CBDP mice received
1.5mg/kg CBDP + saline + saline, sarin mice received 1.5 mg/kg CBDP + 46µg/kg sarin + saline,
and Q-VD-OPh mice received 1.5mg/kg CBDP + 46µg/kg sarin + 20mg/kg Q-VD-OPh.
Animals were treated with a single dose of each treatment and analyzed 2 days post exposure.
Each bar represents the mean ± S.D. per group (CBDP, n=2; sarin, n=3; Q-VD-OPh, n=2). F2,4=
4.242; A p-value < 0.05 was considered significant.
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Figure 33: Alterations of GFAP expression in the hypothalamus at 2 days following exposure
across treatment groups. A1-A3 is an example from a negative control for the staining protocol;
A3, is an overlay of A1 and A2. B1-B3 is an example from a mouse treated with 1.5mg/kg
CBDP; B3, is an overlay of B1 and B2. C1-C3 is an example from a mouse treated with
1.5mg/kg CBDP + 46µg/kg sarin; C3, is an overlay of C1 and C2. D1-D3 is an example from a
mouse treated with 1.5mg/kg CBDP + 46 µg/kg sarin + 20mg/kg Q-VD-OPh; D3 is an overlay of
D1 and D2. Images were captured at 20X magnification. Scale bar represents 100µm.
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Figure 34: Dot plot showing the mean number of GFAP positive cells in µm2 per unit area (641
x 479 µm2) in the hypothalamus of mice across different treatment groups. CBDP mice received
1.5mg/kg CBDP + saline + saline, sarin mice received 1.5 mg/kg CBDP + 46µg/kg sarin + saline,
and Q-VD-OPh mice received 1.5mg/kg CBDP + 46µg/kg sarin + 20mg/kg Q-VD-OPh.
Animals were treated with a single dose of each treatment and analyzed 2 days post exposure.
Each bar represents the mean ± S.D. per group (CBDP, n=2; sarin, n=3; Q-VD-OPh, n=2). F2,4=
3.503; A p-value < 0.05 was considered significant.
NF-κB/p50-50 Immunofluorescent Staining
NF-κB is present in neurons and glial cells in the CNS and plays a crucial role in
neuroinflammatory and immunological responses. Inactive NFκB dimers are localized in the
cytoplasm by IκB whereas active NFκB/p50-p50 homodimers and NFκB/p50-p65 heterodimers
are present in the nucleus. It was unknown which dimer would be predominantly activated in this
study. We used a primary NFκB/p50 antibody to label active anti-inflammatory NFκB/p50-p50
homodimers in the nucleus since they are usually pro-apoptotic. Our primary NFκB/p50
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antibody also labels the NFκB/p105 precursor complex that holds the inactive NFκB/p50-50
dimer in the cytoplasm (Santa Cruz Biotechnology, 2010). Therefore, we analyzed the ratio of
nuclear versus cytoplasmic NFκB/p50-p50 in order to evaluate if sarin or Q-VD-OPh had an
active, inhibitory, or null effect in causing the nuclear translocation of NFκB/p50-p50 in our
study.
An increase in nuclear versus cytoplasmic NFκB/p50-50 expression is an indication of
anti-inflammatory gene transcription thereby inducing a cellular environment promoting
apoptosis. Positive NFκB p50 staining in the dendate gyrus of control and treated animals was
not quantified due to nonspecific positive staining in negative control tissue sections. However,
NFκB p50 staining in the CA2-CA3 regions from negative control mice (Figure 35, A1-A3)
showed no positive staining compared to CBDP (Figure 35, B1-B3), sarin (Figure 35, C1-C3),
and Q-VD-OPh (Figure 35, D1-D3) treated mice. Statistical analysis of cell counts in the CA2CA3 sub-region of mice revealed a significant increase in nuclear NFκB p50 expression
following Q-VD-OPh injection compared to CBDP and sarin treated animals (Figure 36).
Additionally, CBDP treated mice showed a nominal increase in nuclear NFκB p50 expression
than sarin treated animals.
NFκB p50 staining in the piriform cortex from negative control mice (Figure 37, A1-A3)
showed no positive staining compared to CBDP (Figure 37, B1-B3), sarin (Figure 37, C1-C3),
and Q-VD-OPh (Figure 37, D1-D3) treated mice. Statistical analysis of cell counts in the
piriform cortex of mice revealed a significant increase in nuclear NFκB p50 expression following
Q-VD-OPh injection compared to CBDP and sarin treated animals (Figure 38). Additionally,
CBDP treated mice showed a nominal decrease in nuclear NFκB p50 expression than sarin
treated animals.
NFκB p50 staining in the amygdala from negative control mice (Figure 39, A1-A3)
showed no positive staining compared to CBDP (Figure 39, B1-B3), sarin (Figure 39, C1-C3),
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and Q-VD-OPh (Figure 39, D1-D3) treated mice. Statistical analysis of cell counts in the
amygdala of mice revealed a significant increase in nuclear NFκB p50 expression following QVD-OPh injection compared to CBDP and sarin treated animals (Figure 40). Additionally,
CBDP treated mice showed a nominal increase in nuclear NFκB p50 expression than sarin treated
animals.
NFκB p50 staining in the hypothalamus from negative control mice (Figure 41, A1-A3)
showed no positive staining compared to CBDP (Figure 41, B1-B3), sarin (Figure 41, C1-C3),
and Q-VD-OPh (Figure 41, D1-D3) treated mice. Statistical analysis of cell counts in the
hypothalamus of mice revealed a significant increase in nuclear NFκB p50 expression following
Q-VD-OPh injection compared to CBDP and sarin treated animals (Figure 42). Additionally,
CBDP treated mice showed a nominal increase in nuclear NFκB p50 expression than sarin treated
animals.
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Figure 35: Alterations of NF-κB p50 expression in the CA2-CA3 region at 2 days following
exposure across treatment groups. A1-A3 is an example from a negative control for the staining
protocol; A3, is an overlay of A1 and A2. B1-B3 is an example from a mouse treated with
1.5mg/kg CBDP; B3, is an overlay of B1 and B2. C1-C3 is an example from a mouse treated
with 1.5mg/kg CBDP + 46µg/kg sarin; C3, is an overlay of C1 and C2. D1-D3 is an example
from a mouse treated with 1.5mg/kg CBDP + 46 µg/kg sarin + 20mg/kg Q-VD-OPh; D3 is an
overlay of D1 and D2. Images were captured at 40X magnification. Scale bar represents 50µm.
51

Figure 36: Dot plot showing the mean ratio of nuclear versus cytoplasmic NF-κB p50 positive
cells in µm2 per unit area (321 x 240 µm2) in the CA2-CA3 region of mice across different
treatment groups. CBDP mice received 1.5mg/kg CBDP + saline + saline, sarin mice received
1.5 mg/kg CBDP + 46µg/kg sarin + saline, and Q-VD-OPh mice received 1.5mg/kg CBDP +
46µg/kg sarin + 20mg/kg Q-VD-OPh. Animals were treated with a single dose of each treatment
and analyzed 2 days post exposure. Each bar represents the mean ± S.D. per group (CBDP, n=2;
sarin, n=3; Q-VD-OPh, n=2). F2,4= 10.60; A p-value < 0.05 was considered significant (*
p<0.05).
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Figure 37: Alterations of NF-κB p50 expression in the piriform cortex at 2 days following
exposure across treatment groups. A1-A3 is an example from a negative control for the staining
protocol; A3, is an overlay of A1 and A2. B1-B3 is an example from a mouse treated with
1.5mg/kg CBDP; B3, is an overlay of B1 and B2. C1-C3 is an example from a mouse treated
with 1.5mg/kg CBDP + 46µg/kg sarin; C3, is an overlay of C1 and C2. D1-D3 is an example
from a mouse treated with 1.5mg/kg CBDP + 46 µg/kg sarin + 20mg/kg Q-VD-OPh; D3 is an
overlay of D1 and D2. Images were captured at 40X magnification. Scale bar represents 50µm.
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Figure 38: Dot plot showing the mean ratio of nuclear versus cytoplasmic NF-κB p50 positive
cells in µm2 per unit area (321 x 240 µm2) in the piriform cortex of mice across different
treatment groups. CBDP mice received 1.5mg/kg CBDP + saline + saline, sarin mice received
1.5 mg/kg CBDP + 46µg/kg sarin + saline, and Q-VD-OPh mice received 1.5mg/kg CBDP +
46µg/kg sarin + 20mg/kg Q-VD-OPh. Animals were treated with a single dose of each treatment
and analyzed 2 days post exposure. Each bar represents the mean ± S.D. per group (CBDP, n=2;
sarin, n=3; Q-VD-OPh, n=2). F2,4= 67.20; A p-value < 0.05 was considered significant (**
p<0.01).
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Figure 39: Alterations of NF-κB p50 expression in the amygdala at 2 days following exposure
across treatment groups. A1-A3 is an example from a negative control for the staining protocol;
A3, is an overlay of A1 and A2. B1-B3 is an example from a mouse treated with 1.5mg/kg
CBDP; B3, is an overlay of B1 and B2. C1-C3 is an example from a mouse treated with
1.5mg/kg CBDP + 46µg/kg sarin; C3, is an overlay of C1 and C2. D1-D3 is an example from a
mouse treated with 1.5mg/kg CBDP + 46 µg/kg sarin + 20mg/kg Q-VD-OPh; D3 is an overlay of
D1 and D2. Images were captured at 40X magnification. Scale bar represents 50µm.
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Figure 40: Dot plot showing the mean ratio of nuclear versus cytoplasmic NF-κB p50 positive
cells in µm2 per unit area (321 x 240 µm2) in the amygdala of mice across different treatment
groups. CBDP mice received 1.5mg/kg CBDP + saline + saline, sarin mice received 1.5 mg/kg
CBDP + 46µg/kg sarin + saline, and Q-VD-OPh mice received 1.5mg/kg CBDP + 46µg/kg sarin
+ 20mg/kg Q-VD-OPh. Animals were treated with a single dose of each treatment and analyzed
2 days post exposure. Each bar represents the mean ± S.D. per group (CBDP, n=2; sarin, n=3; QVD-OPh, n=2). F2,4= 30.46; A p-value < 0.05 was considered significant (** p<0.01).
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Figure 41: Alterations of NF-κB p50 expression in the hypothalamus at 2 days following
exposure across treatment groups. A1-A3 is an example from a negative control for the staining
protocol; A3, is an overlay of A1 and A2. B1-B3 is an example from a mouse treated with
1.5mg/kg CBDP; B3, is an overlay of B1 and B2. C1-C3 is an example from a mouse treated
with 1.5mg/kg CBDP + 46µg/kg sarin; C3, is an overlay of C1 and C2. D1-D3 is an example
from a mouse treated with 1.5mg/kg CBDP + 46 µg/kg sarin + 20mg/kg Q-VD-OPh; D3 is an
overlay of D1 and D2. Images were captured at 40X magnification. Scale bar represents 50µm.
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Figure 42: Dot plot showing the mean ratio of nuclear versus cytoplasmic NF-κB p50 positive
cells in µm2 per unit area (321 x 240 µm2) in the hypothalamus of mice across different treatment
groups. CBDP mice received 1.5mg/kg CBDP + saline + saline, sarin mice received 1.5 mg/kg
CBDP + 46µg/kg sarin + saline, and Q-VD-OPh mice received 1.5mg/kg CBDP + 46µg/kg sarin
+ 20mg/kg Q-VD-OPh. Animals were treated with a single dose of each treatment and analyzed
2 days post exposure. Each bar represents the mean ± S.D. per group (CBDP, n=2; sarin, n=3; QVD-OPh, n=2). F2,4= 30.45; A p-value < 0.05 was considered significant (** p<0.01).
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IV. Discussion
The main objective of this study was to determine if an in-vivo caspase inhibitor Q-VDOPh, could attenuate sarin induced neuroinflammation and neurodegeneration in specific brain
regions of mice at a two-day time point. The aim of the study was two-fold: 1) Establish
neuroinflammatory and neurodegenerative markers of sarin exposure; and 2) Determine if Q-VDOPh could attenuate sarin induced prolonged or progressive neuroinflammation and
neurodegeneration. We tested the hypothesis using three specific techniques: MALDI Imaging
of whole brain tissues for endogenous OP-biomarkers; GFAP immunofluroescent staining in
brain regions for neuronal injury; and NF-κB p50 immunofluorescent staining in brain regions for
a promotion or lack of apoptotic induced cell death.
MALDI Imaging
It was originally intended to record tissue sample analytes in reflectron positive-ion mode
in order to avoid the production of mass spectra with poor resolution due to peak width
broadening. For the reflectron to be operational, a turbomolecular vacuum pump pressurizes the
flight tube to 8X10-7 mbar in order to redirect ions to the reflector detector (Autoflex Operator
Manual, 2011). Inherent hardware abnormalities with the reflectron turbomolecular vacuum
pump prevented the reflectron ion flight tube to reach nominal pressure. In contrast to the
reflectron vacuum pump system, the linear vacuum pump system is operational at a pressure of
1X10-2 mbar in order to accelerate ions through a linear flight tube (Autoflex Operator Manual,
2011). Thus, all tissue sample mass spectra were recorded in linear positive-ion mode to
facilitate an important first step in the optimization of tissue-washing procedures before MALDITOF imaging analysis.
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The application of organic solvents to tissues before MALDI-TOF analysis is a widely
accepted practice. For instance, Lemaire and colleagues subjected tissue sections from rat brains
to variety of organic solvents before MALDI analysis after noting untreated tissue sections
demonstrated poor signal intensities (2006). They concluded that chloroform and xylene
increased the signal intensity of a number of peptides in the m/z range of 500-1000 among all
tested solvents (Lemaire et al., 2006). The chemical treatment of tissue sections to enhance signal
quality of low molecular weight neuropeptides (less than 5000 m/z) is not limited to brain tissue.
For instance, Leinweber and colleagues (2008) subjected rodent kidney tissue sections to organic
solvent layers before analyzing high molecular weight peptides (greater than 5000 m/z). After
placing kidney sections on top of a sinapinic acid (SA) dissolved in 90% ethanol + 0.5% TX-100,
they verified this treatment yielded the greatest signal intensity of peptides in the 10,000 to
50,000 m/z range (Leinweber et al., 2008).
In our study, we observed that treated tissue sections with organic washes yielded a
greater signal sensitivity compared to untreated tissue sections. However, the spectra observed in
our chemically treated spare sections and our experimental sections were poor due to the presence
of broad peaks. A more detailed inspection of our MALDI-TOF hardware would have revealed
the reflectron turbomolecular pump was not at operational capacity. Despite our limitations of
utilizing MALDI-TOF linear positive-ion mode during the in-situ analysis of mouse brain tissue
sections, we were able to determine that it is necessary to apply an organic solvent to the sections
before analyzing endogenous neuropeptides in the 1000 to 5000 m/z range. Further pursuit of this
study is warranted in order to localize and quantify OP-biomarkers our animal model.
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GFAP and NF-κB Immunofluorescent Staining
The toxic by-products of sub-lethal sarin exposure can cause damage to surrounding
tissue. GFAP expression is a marker for neuronal injury and nuclear NF-κB/p50-p50 expression
is a marker for the transcription of anti-inflammaotry cytokines and hence, inducing a cellular
environment promoting apoptotic cell death. It was hypothesized that Q-VD-OPh will act as a
neuroprotectant by suppressing neuronal injury and may activate NF-κB p50 translocation into
the nucleus. To test this hypothesis, it was originally intended to analyze the dendate gyrus,
CA2-CA3 sub-region, piriform cortex, amygdala, and hypothalamus of mice in saline, CBDP,
sarin, and Q-VD-OPh treated groups (n=3) with GFAP and NF-κB p50 immunofluorescent
stains. Increased GFAP staining with decreased nuclear NF-κB p50 expression in sarin treated
animals would indicate a cellular environment favoring neuronal injury and transcription of antiinflammatory cytokines. On the contrary, decreased GFAP staining with increased nuclear NFκB p50 expression in Q-VD-OPh treated animals would indicate a cellular environment favoring
neuroprotection and transcription of anti-inflammatory cytokines.
Despite the problems presented during tissue sectioning and collection, we were able to
obtain enough viable tissue to evaluate the significance that not all GFAP and NF-κB p50 stained
sections were the same across (saline, n=1; CBDP, n=2; sarin, n=3; Q-VD-OPh, n=2) treatment
groups. Since the saline group presented a low sample number, we quantified and compared the
differences in GFAP and NF-κB p50 expression from CBDP, sarin, and Q-VD-OPh treated
animals. While we were only able to observe positive GFAP staining in the dendate gyrus, we
were able to identify positive GFAP and NF-κB p50 staining in the CA2-CA3 sub-regions,
piriform cortex, amygdala, and hypothalamus from representative animals.
A general trend in GFAP and nuclear NF-κB p50 expression was observed in specific
brain regions of mice across treatment groups. GFAP expression in the dendate gyrus, CA2-CA3
sub-regions, and hypothalamus of CBDP treated mice was less than Q-VD-OPh treated mice.
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However, no discernable difference in GFAP expression was observed in the piriform cortex and
amygdala in CBDP and Q-VD-OPh treated animals. In contrast, nuclear NF-κB p50 expression
in the CA2-CA3 sub-regions, piriform cortex, amygdala, and hypothalamus of CBDP and Q-VDOPh treated mice presented no genuine difference in staining. In contrast, nuclear NF-κB p50
expression in the CA2-CA3 sub-regions, piriform cortex, amygdala, and hypothalamus of Q-VDOPh treated animals showed an upward trend compared to sarin and CBDP treated animals. Most
importantly, in the CA2-CA3 sub-regions, piriform cortex, amygdala, and hypothalamus of sarin
treated animals, there was an upward trend in GFAP expression, and a downward trend in NF-κB
p50 expression compared to Q-VD-OPh treated animals.
The most critical finding in the present study was that GFAP and nuclear NF-κB p50
expression in sarin and Q-VD-OPh treated animals showed opposing trends in expression across
all brain regions examined. The upward trend in GFAP expression and downward trend in
nuclear NF-κB p50 expression suggests that sub-lethal sarin exposure is inducing neuronal injury
in a proinflammatory and anti-apoptotic cellular environment. Furthermore, the downward trend
in GFAP expression and upward trend in nuclear NF-κB p50 expression suggests that Q-VD-OPh
is inducing neuroprotection in an anti-inflammatory and pro-apoptotic cellular environment.
These observations lead to the reasoning that Q-VD-OPh may be effecting the expression of NFκB/p50-p50 and NF-κB/p50-p65 concomitantly.
The point at which a cell becomes pro-apoptotic or anti-apoptotic during OP exposure is
dependent on the expression of active NF-κB/p50-p50 and NF-κB/p50-p65 dimers. Active NFκB dimers exist in a dynamic cross talk with ROS, caspases, and JNK involved in various signal
transduction pathways (Figure 43) (Bubici et al., 2006). OP’s have been shown to disrupt normal
signal transduction pathways regulated by MAPKs (mitogen-activated protein kinases) that lead
to abnormal transcription of intermediate filaments in the CNS (Caughlan et al., 2004;
Damaodaran, Bilska, Rahman, and Abou-Donia, 2002; Damodaran, Mecklai, and Abou-Donia,
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2002). JNK (c-Jun N-terminal kinase) is a member of the MAPK pathway that is activated in
response to numerous extracellular stimuli and different forms of intracellular stress
(Dhanasekaran and Reddy 2008). OP’s have shown to induce ROS production yet the
mechanism remains unknown. However, the positioning of JNK downstream of ROS may
provide an indication to the induction of apoptosis following OP exposure (Matsuzawa and Ichijo
2005; Pham et al., 2004).

Figure 43: NF-κB dimers in a dynamic cross talk with JNK, ROS, and caspases. Active NF-κB
dimers play a central role in the promotion and inhibition of pro-apoptotic molecular players.
Further elucidation as to which active dimer is primarily activated is needed in order to determine
if Q-VD-OPh is an optimal therapeutic in attenuating sub-lethal nerve agent induced
neuropathies.
The observation of an upward trend in nuclear NF-κB/p-50-50 expression in Q-VD-OPh
treated animals compared to sarin treated animals is consistent with recent evidence that 20
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mg/kg of Q-VD-OPh had no effect when administered in adult male C57BL/6J mice (Liu et al.,
2009). On the contrary, a 20 mg/kg Q-VD-OPh administration in adult female C57BL/6J mice
was neuroprotective, consistent with evidence that female mice superbly benefited from Q-VDOPh therapy (Liu et al., 2009; Renolleau et al., 2007). If adult female C57BL/6J mice had been
used in this study, more significant results may have been observed. In addition, a higher number
of animals would validate the hypothesis that Q-VD-OPh is neuroprotective when administered
following sub-lethal sarin exposure.
Future Research
Additional staining with antibodies against additional neuroinflammatory cytokines, e.g.,
IL-6, IL-10, IL-1β, TNF-α, and PGE2 would provide a baseline of neuroinflammation or lack
thereof, in mice exposed to sub-lethal amounts of sarin. It would also be beneficial to stain with
antibodies against NF-κB/p-50-50 homodimers and NF-κB/p-50-65 heterodimers in order to
determine which dimer is predominantly activated following sub-lethal sarin exposure. Further
staining with antibodies against activated caspase 3, 8, and 9 would determine apoptotic cell
death in the brain and provide an essential complement to neuroinflammatory cytokine staining.
A more extensive study harvesting the collection of tissue sections at multiple time points
(8 hrs, 24 hrs, two days, and two weeks) following sarin exposure and Q-VD-OPh administration
would allow a more thorough understanding of OP-induced delayed neurodegeneration and
neuroinflammation. It would be beneficial to include more time points to in order to determine
the optimal period of NF-κB/p-50-50 or NF-κB/p-50-65 activation. Most importantly, the use of
adult female C57BL/6J mice may provide as a better model for studying the ability of Q-VD-OPh
to attenuate neurodegeneration and neuroinflammation following sub-lethal sarin exposure.
Additionally, ensuring the generation of proteomic profiles from sarin and Q-VD-OPh tissue
sections is captured in reflectron mode would allow for the future localization of sarin and Q-VDOPh in specific brain regions by comparison with control tissues lacking these agents.
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Conclusion
Sarin is an OP ester that remains an active threat to military personnel and more
importantly, a vulnerable civilian population. It is only recently that current research efforts are
pursuing new therapies to counter act OP poisoning for current treatments do not address any of
the long-term side effects associated with nerve agent exposure. The investigation of new
therapies starts with our current understanding of delayed OP induced neuropathies. Soldiers and
civilians of past nerve agent attacks developed progressive declines in cognitive ability evident in
studies linking neurohistopathological lesions to brain regions responsible for the regulation of
memories, mood, judgment, emotions, and learning (Spradling, 2011). The delayed effects
persisted even after the administration of CANA-MARK I prophylactics within the crucial 40
minute window they remain effective. This opened a window to innovative research paradigms
that extended beyond the emphasis of regenerating AChE and managing seizures.
The present pilot study focused on the capability of an in-vivo caspase inhibitor to
attenuate sarin-induced, prolonged or progressive CNS neuroinflammation and
neurodegeneration in adult male C57BL/6J mice at a two-day time point. Mice were subjected to
a dosing sequence that mimics chronic OP toxicity in humans via the injection of 1.5 mg/kg
CBDP before a 0.5 LD50 injection of sarin. To ensure that our caspase inhibitor provided
neuroprotection beyond the limitations of CANA-MARK-1 treatments, mice received a 20 mg/kg
injection of Q-VD-OPh 40 minutes after sarin injections. MALDI imaging of whole brain tissue
sections for endogenous OP-biomarkers captured in linear positive ion mode presented spectra
with poor mass resolution and broad peaks. Most notably however, the staining methods for
GFAP and nuclear NF-κB p50 expression successfully labeled positive cells in all five brain
regions examined with the exception of NF-κB p50 staining in the dendate gyrus.
The discovery that GFAP and nuclear NF-κB p50 expression in sarin and Q-VD-OPh
treated animals operates in an inverse manner unlocks a gateway for the investigation of
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additional neurodegenerative and neuroinflammatory alterations following sub-lethal nerve agent
exposure. For instance, active NF-κB dimers exist in a dynamic cross talk with JNK, ROS, and
caspases and play a central role in the promotion and inhibition of pro-apoptotic molecular
players (Bubici, 2006). Likewise, GFAP is an indicator for neuronal injury that upon activation
forms a glial scar around damaged tissue (Sofroniew and Vinters 2010). While further validation
is warranted, the upward trend in GFAP expression and downward trend in nuclear NF-κB p50
expression suggests that sub-lethal sarin exposure is inducing neuronal injury in a
proinflammatory and anti-apoptotic cellular environment. On the contrary, the downward trend
in GFAP expression and upward trend in nuclear NF-κB p50 expression suggests that Q-VD-OPh
is inducing neuroprotection in an anti-inflammatory and pro-apoptotic cellular environment.
Future research efforts would validate the neuroprotective ability of Q-VD-OPh to attenuate the
delayed type neuropathies induced by sub-lethal nerve agent exposure.
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V. Appendix

Treatment

Animal #

DG

CA2-CA3

Pir

Amy

Hypo

Saline

326

153

148

28

17

94

N/A

N/A

N/A

N/A

N/A

330

186

191

27

62

118

331

113

105

19

17

66

149.5

148

23

39.5

92

334

316

328

161

130

185

335

206

150

173

87

183

336

289

234

53

77

204

270.3

237.3

129

98

190.7

339

261

236

54

48

185

341

125

130

42

34

82

193

183

96

41

133.5

Avg. N/A

CBDP

Avg. (n=2)

Sarin

Avg. (n=3)

QVD

Avg. (n=2)

Table 1. GFAP immunofluorescent staining: This table summarizes the raw number of
positively labeled GFAP cells from each brain region assessed for statistical analysis. Negative
controls were stained to confirm the staining method was performed properly; however, counts
were not included in the analysis. Counts from one section per animal were averaged to obtain a
mean cell count for each region. Cell counts from saline regions were disregarded because of a
small sample size (n=1).
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CA2-CA3

Piriform Cortex

Amygdala

Hypothalamus

Drug

Animal
#

(c)
Stain

(n)
Stain

n stain
c stain

(c)
Stain

(n)
Stain

n stain
c stain

(c)
Stain

(n)
Stain

n stain
c stain

(c)
Stain

(n)
Stain

n stain
c stain

Saline

326

70

7

0.100

14

2

0.143

62

7

0.113

69

7

0.101

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

330

39

6

0.154

34

5

0.147

16

2

0.125

28

5

0.179

331

21

3

0.143

22

3

0.136

14

2

0.143

27

4

0.148

30

4.5

0.149

28

4

0.142

15

2

0.134

27.5

4.5

0.164

334

48

5

0.104

32

5

0.156

27

4

0.148

23

3

0.130

335

27

4

0.148

16

2

0.125

18

2

0.111

19

3

0.158

336

29

4

0.138

20

3

0.150

15

2

0.133

16

3

0.188

34.7

4.3

0.130

22.7

3.3

0.144

20

2.7

0.131

19.3

3

0.159

339

60

22

0.367

57

21

0.368

33

10

0.303

58

18

0.310

341

24

6

0.250

23

10

0.435

13

5

0.385

19

6

0.316

42

14

0.309

40

15.5

0.402

23

7.5

0.344

38.5

12

0.313

Avg. N/A

CBDP

Avg. (n=2)

Sarin

Avg. (n=3)

QVD

Avg. (n=2)

Table 2. NF-κB p50 immunofluorescent staining: This table summarizes the raw ratio of
nuclear (n) versus cytoplasmic (c) positively labeled cells from each brain region assessed for
statistical analysis. Negative controls were stained to confirm the staining method was performed
properly; however, counts were not included in the analysis. Cell counts from one section per
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animal were averaged to obtain a mean ratio of nuclear versus cytoplasmic NF-κB p50 for each
region. Cell counts from saline regions were disregarded because of a small sample size (n=1).

69

VI. References
Abdel-Rahman, A., Shetty, A.K., Abou-Donia, M.B. (2002). Acute Exposure to Sarin Increases
Blood Brain Barrier Permeability and Induces Neuropathological Changes In the Rat
Brain: Dose-Response Relationships. Neuroscience, 113(3), 721-741.
Abou-Donia, M. B. (2003). Organophosphorus Ester-Induced Chronic Neurotoxicity. Archives of
Environmental Health, 58(8), 484-497.
Abou-Donia, M. B., Abdel-Rahman, A., Goldstein, L.B., Dechkovskaia, A.M., Shah, D.U.,
Bullman, S.L., Khan, W.A. (2003). Sensorimotor deficits and increased brain nicotinic
acetylcholine receptors following exposure to chlorpyrifos and/or nicotine in rats.
Archives of Toxicology, 77(8), 452-458.
Abrahamson, E.E., Ikonomovic, M.D., Ciallella, J.R., Hope, C.E., Paljug, W.R., Isanski, B.A.,
Flood, D.G., Cark, R.S., Kosky, S.T. (2006). Caspase inhibition therapy abolishes brain
trauma-induced increases in Abeta peptide: implications for clinical outcome.
[Comparative Study Research Support, N.I.H., Extramural]. Experimental neurology,
197(2), 437-450. doi: 10.1016/j.expneurol.2005.10.011
Abu-Qare, A.W. and M.B. Abou-Donia. (2002). Sarin: health effects, metabolism, and methods
of analysis. Food and Chemical Toxicology: an international journal published for the
British Industrial Biological Research Association, 40(10), 1327-1333.
Ashcroft, A. E. (1997). Ionization Methods in Organic Mass Spectrometry. In N.W. Barnett
(Ed.), Ionization Methods in Organic Mass Spectrometry (pp. 20-24). Cambridge: The
Royal Society of Chemistry.
Autoflex Operator Manual: Vacuum System. (2001). In Bruker Daltonics (Ed.), (1 ed., pp. 1-6).
Bremen, Germany: Bruker Daltonic Bremen.
Barut, Ş., Ünlü, A.Y., Karaoğlan, A.,Tunçdemir, M., Dağistanli, K.F., Öztürk, M., Çolak, A.
(2005). The neuroprotective effects of z-DEVD.fmk, a caspase-3 inhibitor, on traumatic
spinal cord injury in rats. Surgical Neurology, 64, 213-220.
Braun, J. S., Prass, K., Dirnagl, U., Meisel, A., Meisel, C. (2007). Protection from brain damage
and bacterial infection in murine stroke by the novel caspase-inhibitor Q-VD-OPh.
Experimental neurology, 206(2), 183-191.
Brown, T. L. (2004). Q-VD-OPh, Next Generation Caspase Inhibitor. In P.K. Lauf & N.C.
Adragna (Eds.), Cell Volume and Signaling (pp. 293-300). New York City: Springer
Science + Business Media, Inc. (Vol. 559).

70

Bubici, C., Papa, S., Dean, K., Franzoso, G. (2006). Mutual cross-talk between reactive oxygen
species and nuclear factor-kappa B: molecular basis and biological significance.
Oncogene, 25, 6731-6748.
Bullman, T. A., Mahan, C.M., Kang, H.K., Page, W.F. (2005). Mortality in US Army Gulf War
veterans exposed to 1991 Khamisiyah chemical munitions destruction. [Research
Support, U.S. Gov't, Non-P.H.S.]. American journal of public health, 95(8), 1382-1388.
doi: 10.2105/AJPH.2004.045799
Carter, W. G., Tarhoni, M., Rathbone, A.J., Ray, D.E. (2011). Differential protein adduction by
seven organophosphorus pesticides in both brain and thymus. Human and Experimental
Toxicology, 26(4), 347-353.
Caserta, T. M., Smith, A.N., Gultice, A.D., Reedy, M.A., Brown, T.L. (2003). Q-VD-OPh, a
broad spectrum caspase inhibitor with potent antiapoptotic properties. Apoptosis, 8, 345352.
Casida, J.E. and G.B. Quistand (2004). Organophosphate Toxicology: Safety Aspects of
Nonacetylcholinesterase Secondary Targets. [Review]. Chemical Research in Toxicology,
17(8), 983-998.
Caughlan, A., Newhouse, K., Namgung, U., Xia, Z. (2004). Chlorpyrifos induces apoptosis in rat
cortical neurons that is regulated by a balance between p38 and ERK/JNK MAP kinases.
Toxicological Sciences 126, 125-134.
Chao, L. L., Rothlind, J.C., Cardenas, V.A., Meyerhoff, D.J., Weiner, M.W. (2010). Effects of
low-level exposure to sarin and cyclosarin during the 1991 Gulf War on brain function
and brain structure in US veterans. [Research Support, N.I.H., Extramural Research
Support, U.S. Gov't, Non-P.H.S.]. Neurotoxicology, 31(5), 493-501. doi:
10.1016/j.neuro.2010.05.006
Chauvier, D., Ankri, S., Charriaut-Marlangue, C., Casimir, R., Jacotot, E. (2006). Broad-spectrum
caspase inhibitors: from myth to reality? Cell Death and Differentiation, 14, 387-391.
Clement, J.G. and N. Erhardt (1990). Serum carboxylesterase activity in various strains of rats:
sensitivity to inhibition by CBDP (2-/o-cresyl/4H 1 3 2 benzodioxaphosphorin-2-oxide).
Archives of Toxicology, 64(5), 414-416.
Çolak, A., Antar, V., Karaoğlan, A., Akdemir, O., Sahan, E., Çelik, Ö., Sağmanligil, A. (2009).
Q-VD-OPh, a pancaspase inhibitor, reduces trauma-induced apoptosis and improves the
recovery of hind-limb function in rats after spinal cord injury. Neurosurgery
Collombet, J. (2011). Nerve agent intoxication: Recent neuropathophysiological findings and
subsequent impact on medical management prospects. Toxicology and Applied
Pharmacology, 255(3), 229-241.
Costa, L. G. (2006). Current issues in organophosphate toxicology. Clinica Chimica Acta, 366(12), 1-13.

71

Damaodaran, T. V., Bilska, M.A., Rahman, A.A., Abou-Donia, M.B. (2002). Sarin causes early
differential alteration and persistent overexpression in mRNAs coding for glial fibrillary
acidic protein (GFAP) and vimentin genes in the central nervous system of rats.
Neurochemcial research, 27, 407-415.
Damodaran, T. V., Mecklai, A.A., Abou-Donia, M.B. (2002). Sarin causes altered time course of
mRNA expression of alpha tubulin in the central nervous system of rats. Neurochemcial
research, 27, 177-181.
Dhanasekaran, D.N. and E.P. Reddy (2008). JNK Signaling in Apoptosis. Oncogene, 27(48),
6245-6251.
Dickerson, B.C. and H. Eichenbaum (2010). The Episodic Memory System: Neurocircuitry and
Disorders. Neuropsychopharmacology Reviews, 35, 86-104.
Doctor, B.P. and A. Saxena (2005). Bioscavengers for the protection of humans against
organophosphate toxicity Chemico-biological interactions, 157, 167-171.
Domon, B. and R. Aebersold (2006). Mass Spectrometry and Protein Analysis. Science,
312(5771), 212-217.
El-Demerdash, F. M. (2011). Lipid peroxidation, oxidative stress and acetylcholinesterase in rat
brain exposed to organophosphate and pyrethroid insecticides. Food and Chemical
Toxicology, 49(6), 1346-1352.
Ergun, S. S., Ozturk, K., Su, O., Gursoy, E.B., Ugurad, I., Yuksel, G. (2008). Delayed
Neuropathy Due to Organophosphate Insecticide Injection in an Attempt to Commit
Suicide Hand, 4(1), 84-87.
Flensburg, J., Haid, D., Blomberg, J., Bielawski, J., Ivansson, D. (2004). Applications and
performance of a MALDI-ToF mass spectrometer with quadratic field reflectron
technology. Journal of Biochemical and Biophysical Methods, 60(3), 319-334.
Flex Imaging 2.1 User Manual: Data Processing. (2008). In Bruker Daltonics (Ed.), (2 ed., pp. 548). Bremen, Germany: Bruker Daltonic Bremen.
Fournier, I., Robert, D., Salzet, M. (2003). Direct analysis of neuropeptides by in-situ MALDITOF mass spectrometry in the rat brain. Neuroendocrinology Letters, 24(1/2), 9-14.
Fulda, S. and K.M. Debatin (2006). Extrinsic versus intrinsic apoptosis pathways in anticancer
chemotherapy. Oncogene, 25, 4798-4811.
Ghosh, S., May, M.J., Kopp, E.B. (1998). NF-kappa B and Rel proteins: evolutionary conserved
mediators of immune responses. Annual Review of Immunology, 16, 225-260.
Goodman, L.S., Gilman, A., Brunton, L.L., Lazo, J.S., Parker, K.L. (2006). Goodman & Gilman's
the pharmacological basis of therapeutics (11 ed.). New York: McGrawHill.
72

Grauer, E., Chapman, S., Rabinovitz, I., Raveh, L., Weissman, B., Kadar, T., Allon, N. (2008).
Single whole-body exposure to sarin vapor in rats: Long-term neuronal and behavioral
deficits. Toxicology and Applied Pharmacology, 227(2), 265-274.
Hurst, G., Tuorinsky, S., Madsen, J., Newmark, J., Hill, J., Boardman, C., Dawson, J. (Ed.).
(2007). Medical Management of Chemical Casualties Handbook: Nerve Agents (4th ed.).
Aberdeen Proving Ground, MD: U.S. Government Printing Office.
Inoue, S., Browne, G., Melino, G., Cohen, G.M. (2009). Ordering of caspases in cells undergoing
apoptosis by the intrinsic pathway. Cell Death and Differentiation, 16, 1053-1061.
Jaga, K. and C. Dharmani (2007). The interrelation between organophosphate toxicity and the
epidemiology of depression and suicide. Reviews on Environmental Health, 22(1), 57-74.
Jamal, G. (1997). Neurological syndromes of organophosphorus compounds. Adverse Drug
Reactions and Toxicological Reviews, 16, 133-170.
Jimmerson, V. R., Shih, T.M, Maxwell, D.M., Kaminskis, A., Mailman, R.B. (1989). The effect
of 2-(o-cresyl)-4H-1:3:2-benzodioxaphosphorin-2-oxide on tissue cholinesterase and
carboxylesterase activities of the rat. Fundamental and Applied Toxicology, 13(3), 568575.
Jokanovic, M. (2009). Current Understanding of the mechanisms involved in metabolic
detoxification of warefare nerve agents. Toxicology Letters 188, 1-10.
Jokanovic, M. and M. Kosanovic (2010). Neurotoxic effects in patients poisoned with
organophosphorus pesticides. Environmental Toxicology and Pharmacology, 29(3), 195201.
Kadar, T., Shapira, S., Cohen, G., Sahar, R., Alkalay, D., Raveh, L. (1995). Sarin-induced
neuropathy in rats. Human and Experimental Toxicology, 14(3), 252-259.
Kaltschmidt, C., Kaltschmidt, B., Neumann, H., Wekerle, H., Baeuerle, P.A. (1994). Constituitive
NF-kappa B activity in neurons. Molecular and Cellullar Biology 14, 3981-3992.
Kilburn, K. H. (1999). Evidence for chronic neurobehavioral impairment from chlorpyrifosa, and
organophosphate insectide (Dursban) used indoors. Environmental Epidemiology and
Toxicology, 1, 153-162.
Kurnosenko, S. and E. Moskovets (2010). On the high-resolution mass analysis of the product
ions in tandem time-of-flight (TOF/TOF) mass spectrometers using a time-dependent reacceleration technique. Rapid Communications in Mass Spectrometry, 24(1), 63-74.
Leinweber, B. D., Tsaprailis, G., Monks, T.J., Lau, S.S. (2008). Improved MALDI-TOF Imaging
Yields Increased Protein Signals at High Molecular Mass. Journal of the American
Society for Mass Spectrometry, 20(1), 89-95.
Lemaire, R., Wisztorski, M., Desmons, A.,Tabet, J.C., Day, R., Salzet, M., Fournier, I. (2006).
MALDI-MS Direct Tissue Analysis of Proteins: Improving Signal Sensitivity Using
Organic Treatments. Journal of Analytical Chemistry, 78(20), 7145-7153.
73

Levsen, K., Schiebel, H.M., Terlouw, J.K., Jobst, K.J., Elend, M., Preiss, A., Thiele, H.,
Ingendoh, A. (2007). Even-electron ions: a systematic study of the neutral species lost in
the dissociation of quasi-molecular ions. Journal of Mass Spectrometry, 42(8), 10241044.
Li, H., Colbourne, F., Sun, P., Zhao, Z., Buchan, A.M., Ladecola, C. (2000). Caspase inhibitors
reduce neuronal injury after focal but not global cerebral ischemia in rats. Stroke, 31(1),
176-182.
Liu, F., Li, Z., Li, J., Siegel, C., Yuan, R., McCullough, D.L. (2009). Sex Differences in Caspase
Activation after Experimental Stroke. Stroke, 40(5), 1842-1848.
Majumdar, D., Roszak, S., Leszczynski, J. (2006). Probing the Acetylcholinesterase Inhibition of
Sarin: A Comparitive Interaction Study of the Inhibitor and Acetylcholine with a Model
Enzyme Cavity. The Journal of Physical Chemistry, 110(27), 13597-13607.
Masoud, A., Kiran, R., Sandhir, R. (2011). Modulation of dopaminergic system and
neurobehavioral functions in delayed neuropathy induced by organophosphates.
Toxicology Mechanisms and Methods, 21(1), 1-5.
Masson, P. (2011). Evolution of and perspectives on therapeutic approaches to nerve agent
poisoning. Toxicology Letters, 206(1), 5-13.
Matsuzawa, A. and H. Ichijo (2005). Stress-responsive protein kinases in redox-regulated
apoptosis signaling. Antioxidants and Redox Signaling, 7(3-4), 472-481.
Mattson, M. P., Culmsee, C., Yu, Z., Camandola, S. . (2000). Roles of nuclear factor kappaB in
neuronal survival and plasticity. Journal of Neurochemistry 74, 443-456.
McCauley, L. A., Rischitelli, G., Lambert, W.E., Lasarev, M., Sticker, D.L., Spencer, P.S. (2001).
Symptoms of Gulf War veterans possibly exposed to organophosphate chemical warfare
agents at Khamisiyah, Iraq. International Journal of occupational and environmental
health: official journal of the International Commission of Occupational Health, 7(2),
79-89.
McDonough, J.H. and T.M. Shih (1997). Neuropharmacological mechanisms of nerve agentinduced seizure and neuropathology. Journal of Epidemiology 21(5), 559-579.
Meffert, M.K. and D. Baltimore (2005). Physiological functions for brain NF-kappaB. Trends in
Neurosciences, 28, 37-43.
Melnikov, V.Y., Faubel, S., Siegmund, B., Lucia, M.S., Ljubanovic, D., Edelstein, C.L. (2002).
Neutrophil-independent mechanisms of caspase-1–and IL-18–mediated ischemic acute
tubular necrosis in mice. The Journal of Clinical Investigation, 110(8), 1083-1091.

74

Moretto, A., Tiramani, M., Colosio, C. (2011). Long-Term Neurotoxicological Effects of
Anticholinesterases after either Acute or Chronic Exposure. In T. Satoh & R.C. Gupta
(Ed.), Anticholinesterase Pesticides: Metabolism, Neurotoxicity, and Epidemiology.
Hoboken: John Wiley & Sons, Inc.
Morita, H., Yanagisawa, N., Nakajima, T., Shimizu, M., Hirabayashi, H., Okudera, H., Nohara,
M., Midorikawa, Y., Mimura, S. (1995). Sarin poisoning in Matsumoto, Japan. Lancet,
346(8970), 290-293.
Muddiman, D. C., Bakhtiar, R., Hofstadler, S.A., Smith, R.D. (1997). Matrix-Assisted Laser
Desorption/Ionization Mass Spectrometry. Instrumentation and Applications. Journal of
Chemical Education, 74(11), 1288.
Newmark, J. (2004). The birth of nerve agent warfare. Neurology 62(9), 1590-1596.
Nishikori, M. (2005). Classical and Alternative NF-κB Activation Pathways and Their Roles in
Lymphoid Malignancies. Journal of Clinical and Experimental Hematopathology, 45(1),
15-24.
O'Neill, L.A. and C. Kaltschmidt (1997). NF-kappa B: a crucial transcription factor for glial and
neuronal cell function. Trends in Neurosciences, 20, 252-258.
Okumura, T., Suzuki, K., Fukuda, A., Kohama, A., Takasu, N., Ishimatsu, S., Hinohara, S.
(1998). The Tokyo Subway Sarin Attack: Disaster Management, Part 1: Community
Emergency Response. Academic Emergency Medicine, 5(6), 613-617.
Paxinos, G. and K.B.J. Franklin (2007). The Mouse Brain in Stereotaxic Coordinates (3 ed.):
Elsevier Science.
Petras, J. M. (1994). Neurology and neuropathology of Soman-induced brain injury: an
overview. Journal of the Experimental Analysis of Behavior, 61(2), 319-329.
Pham, C. G., Bubici, C., Zazzeroni, F., Papa, S., Jones, J., Alvarez, K., Jayawardena, S., De
Smaele, E., Cong, R., Beaumont, C., Torti, F.M., Torti, S.V., Franzoso, G. (2004).
Ferritin heavy chain upregulation by NF-kappaB inhibits TNF alpha-induced apoptosis
by suppressing reactive oxygen species. Cell 119(4), 529-542.
Platt, B. and G. Riedel (2011). The cholinergic system, EEG and sleep. Behavioral Brain
Research, 221(2), 499-504.
Popov, G., Popov, T., Zey, J. (2008). Aspects of Terrorism: Threat and Use of Toxic Chemical
Substances. Journal of the Institute of Justice and International Studies, 221.
Quistad, G. B., Barlow, C., Winrow, C.J., Sparks, S.E., Casida, J.E. (2003). Evidence that mouse
brain neuropathy target esterase is a lysophospholipase Proceedings of the National
Academy of Sciences of the United States of America, 100(13), 7983-7987.
Rappsilbera, J., Moniatteb, M., Nielsenb, M.L., Podtelejnikovb, A.V., Mann, M. (2003).
Experiences and perspectives of MALDI MS and MS/MS in proteomic research.
International Journal of Mass Spectrometry, 226(1), 223-237.
75

Read, R. W. (2011). Applications of Mass Spectrometry in Investigations of Alleged Use of
Chemical Warfare Agents. In J. Banoub (ed.), Detection of Biological Agents for the
Prevention of Bioterrorism (pp. 201-219). Dordrecht: Springer (Vol. 1).
Renolleau, S., Fau, S., Goyenvalle, C., Joly, L.M., Chauvier, D., Jacotot, E., Mariani, J.,
Charriaut-Marlangue, C. (2007). Specific Caspase Inhibitor Q-VD-OPh prevents neonatal
stroke in P7 rat: a role for gender. Journal of Neurochemistry, 100(4), 1062-1071.
Reyzer, M.L. and R.M. Caprioli (2007). MALDI-MS-based imaging of small molecules and
proteins in tissues. Current Opinion in Chemical Biology, 11(1), 29-35.
Rubino, F. M., Pitton, M., Fabio, D.D., Colombi, A. (2009). Toward an “omic” physiopathology
of reactive chemicals: Thirty years of mass spectrometric study of the protein adducts
with endogenous and xenobiotic compounds. Mass Spectrometry Reviews, 28(5), 725784.
Santa Cruz Biotechnology, Inc. (2010). NFκB p50 (NLS) sc-114. Santa Cruz, California.
Sawchenko, P.E. and L.W. Swanson (1990). Organization of CRF Immunoreactive Cells and
Fibers in the Rat Brain: Immunohistochemical Studies. In E.B. De Souza & C.B.
Nemeroff (Eds.), Corticotropin-Releasing Factor: Basic and Clinical Studies of a
Neuropeptide (pp. 30-46). Boca Raton: CRC Press, Inc.
Schier, J.G. and R.S. Hoffman (2004). Treatment of sarin exposure. The Journal of the American
Medical Association, 291(2), 182-183.
Seeley, E. H., Oppenheimer, S. R., Mi, D., Chaurand, P., Caprioli, R. M. (2008). Enhancement of
protein sensitivity for MALDI imaging mass spectrometry after chemical treatment of
tissue sections. [Research Support, N.I.H., Extramural]. Journal of the American Society
for Mass Spectrometry, 19(8), 1069-1077. doi: 10.1016/j.jasms.2008.03.016
Segura-Aguilar, J. and R.M. Kostrzewa (2004). Neurotoxins and Neurotoxic Species Implicated
in Neurodegeneration. Neurotoxicity Research, 6(7-8), 615-630.
Shen, T., Tai, K., Henchman, R.H., McCammon, J.A. (2002). Molecular Dynamics of
Acetylcholinesterase. Accounts of Chemical Research, 35(6), 332-340.
Sidell, F. R., Newmark, J., McDonough, J.H. (2008). Nerve Agents. In M. Shirley and D.
Tuorinsky (Ed.), Medical Aspects of Chemical Warfare (pp. 155-220). Washington, DC:
Office of The Surgeon General at TMM Publications. Retrieved from
http://www.bordeninstitute.army.mil/publishedvolumes/chemwarfare/Ch5pg155-220.pdf.
Simon, G.M. and B.F. Cravatt (2010). Activity-based Proteomics of Enzyme Superfamilies:
Serine Hydrolases as a Case Study. The Journal of Biological Chemistry 285(15), 1105111055.
Singh, K. A. and Y. Jiang (2004). Differential activation of NF-κB/RelA-p50 and NF-κB/p50-50
in control and alcohol-drinking rats subjected to carrageenin-induced pleurisy. Mediators
of Inflammation, 13(4), 255-262.
76

Sofroniew, M.V. and H.V. Vinters (2010). Astrocytes: biology and pathology. Acta
Neuropathologica, 119, 7-35.
Southerland, B., Kulkarni-Datar, K., Keoni, C., Bricker, R., Jr. Grunwald, C.W., Ketcha, M.D.,
Hern, E., Cool, R.D., Brown, L.T. (2010). Q-VE-OPh, a Negative Control for OPhenoxy-Conjugated Caspase Inhibitors. Journal of Cell Death, 3, 33-40.
Spradling, K. D., Lumley, L.A., Robison, C.L., Meyerhoff, J.L., Dillman, J.F. (2011).
Transcriptional responses of the nerve agent-sensitive brain regions amygdala,
hippocampus, piriform cortex, septum, and thalamus following exposure to the
organophosphonate anticholinesterase sarin. Journal of Neuroinflammation, 8(84).
Spradling, K.D. and J.F. Dillman III. (2011). The Molecular Toxicology of Chemical Warfare
Nerve Agents. In J.C. Fishbein (Ed.), Advances in Molecular Toxicology (pp. 112-138).
Amsterdam: Elsevier (Vol. 5).
Stoeckli, M., Chaurand, P., Hallahan, D.E., Caprioli, R.M. (2001). Imaging mass spectrometry: A
new technology for the analysis of protein expression in mammalian tissues. Nature
Medicine, 7(4), 493-496.
Stoll, R. and F.W. Rollgen (1981). Thermal desorption of quasimolecular ions. Organic Mass
Spectrometry, 16(2), 72-75.
Tebourbi, O., Sakly, M., Rhouma, K.B. (2011). Molecular Mechanisms of Pesticide Toxicity. In
M. Stoytcheva (Ed.), Pesticides in the Modern World - Pests Control and Pesticides
Exposure and Toxicity Assessment (pp. 297-332). InTech.
Thompson, C. M., Prins, J.M., George, K.M. (2010). Mass Spectrometric Analyses of
Organophosphate Insecticide Oxon Protein Adducts. Environmental Health Perspectives,
118(1), 11-19.
Trapp, R. (2006). Worldwide governmental efforts to locate and destroy chemical weapons and
weapons materials: minimizing risk in transport and destruction. Annuals of the New
York Academy of Sciences, 1076, 527-539.
Trump, B. E., Berezesky, I.K., Chang, S H., Phelps, P.C. (1997). The Pathways of Cell Death:
Oncosis, Apoptosis, and Necrosis. Toxicologic Pathology, 25(1), 82-88. doi:
10.1177/019262339702500116
Van Cruchten, S. and W. Van Den Broeck (2002). Morphological and Biochemical Aspects of
Apoptosis, Oncosis and Necrosis. Anatomia, Histologia, Embryologia, 31, 214-223.
Van Noorden, C. J. (2001). The history of Z-VAD-FMK, a tool for understanding the
significance of caspase inhibition. Acta Histochemica, 103, 241-251.
Weston, D. J. (2010). Ambient ionization mass spectrometry: current understanding of
mechanistic theory; analytical performance and application areas. Analyst, 135(4), 661668.

77

White, R. F., Proctor, S.P., Heeren, T., Wolfe, J., Krengel, M., Vasterling, J., Lindem, K., Heaton,
K.J., Sutker, P., Ozonoff, D.M. (2001). Neuropsychological function in Gulf War
veterans: relationships to self-reported toxicant exposures. American Journal of
Industrial Medicine, 40(1), 42-54.
Yanagisawa, N., Morita, H., Nakajima, T. (2006). Sarin experiences in Japan: Acute toxicity and
long-term effects. Journal of the Neurological Sciences, 249(1), 76-85.

78

